

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/68, C12P 19/34, C12N 15/64, 9/00, 1/20, 15/00, C07H 21/02	A1	(11) International Publication Number: WO 97/09451 (43) International Publication Date: 13 March 1997 (13.03.97)
(21) International Application Number: PCT/US96/14189 (22) International Filing Date: 6 September 1996 (06.09.96) (30) Priority Data: 08/525,057 8 September 1995 (08.09.95) US 08/537,397 2 October 1995 (02.10.95) US 08/537,400 2 October 1995 (02.10.95) US 08/576,759 21 December 1995 (21.12.95) US Not furnished 14 August 1996 (14.08.96) US (71)(72) Applicants and Inventors: CHATTERJEE, Deb, K. [US/US]; 6 Forest Ridge Court, N. Potomac, MD 20878 (US). HUGHES, A., John, Jr. [US/US]; 19444 St. Johns- bury Lane, Germantown, MD 20876 (US). (74) Agents: ESMOND, Robert, W. et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., Suite 600, 1100 New York Avenue, N.W., Washington, DC 20005-3934 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	
(54) Title: CLONED DNA POLYMERASES FROM THERMOTOGA AND MUTANTS THEREOF		
(57) Abstract <p>The invention relates to a substantially pure thermostable DNA polymerase from <i>Thermotoga</i> (<i>Tne</i> and <i>Tma</i>) and mutants thereof. The <i>Tne</i> DNA polymerase has a molecular weight of about 100 kilodaltons and is more thermostable than <i>Taq</i> DNA polymerase. The mutant DNA polymerase has at least one mutation selected from the group consisting of (1) a first mutation that substantially reduces or eliminates 3'→5' exonuclease activity of said DNA polymerase; (2) a second mutation that substantially reduces or eliminates 5'→3' exonuclease activity of said DNA polymerase; (3) a third mutation in the O helix of said DNA polymerase resulting in said DNA polymerase becoming non-discriminating against dideoxynucleotides. The present invention also relates to the cloning and expression of the wild type or mutant DNA polymerases in <i>E. coli</i>, to DNA molecules containing the cloned gene, and to host cells which express said genes. The DNA polymerases of the invention may be used in well-known DNA sequencing, labeling, amplification and cDNA synthesis reactions.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

Cloned DNA Polymerases from *Thermotoga* and Mutants Thereof

Background of the Invention

Field of the Invention

5 The present invention relates to a substantially pure thermostable DNA polymerase. Specifically, the DNA polymerase of the present invention is a *Thermotoga* DNA polymerase and more specifically a *Thermotoga neapolitana* (*Tne*) DNA polymerase or *Thermotoga maritima* (*Tma*) DNA polymerase. Preferably, the polymerase has a molecular weight of about 100 kilodaltons. The
10 present invention also relates to the cloning and expression of the *Thermotoga* DNA polymerase in *E. coli*, to DNA molecules containing the cloned gene, and to hosts which express said genes. The DNA polymerase of the present invention may be used in DNA sequencing, amplification reactions, and cDNA synthesis.

 This invention also relates to mutants of the *Thermotoga* DNA
15 polymerase, including *Tne* and *Tma* DNA polymerase. Specifically, the DNA polymerases of the present invention have mutations which substantially reduce 3'→5' exonuclease activity; mutations resulting in the ability of the mutant DNA polymerase to incorporate dideoxynucleotides into a DNA molecule about as
20 efficiently as deoxynucleotides; and mutations which substantially reduce 5'→3' exonuclease activity. The *Thermotoga* (e.g., *Tne* and *Tma*) mutant DNA polymerase of this invention can have one or more of these properties. These DNA polymerase mutants may also be used in DNA sequencing, amplification reactions, and cDNA synthesis.

 The present invention is also directed to novel mutants of other DNA
25 polymerases which have substantially reduced 5'-3' exonuclease activity.

Background Information

DNA polymerases synthesize the formation of DNA molecules which are complementary to a DNA template. Upon hybridization of a primer to the single-stranded DNA template, polymerases synthesize DNA in the 5' to 3' direction, successively adding nucleotides to the 3'-hydroxyl group of the growing strand. Thus, in the presence of deoxyribonucleoside triphosphates (dNTPs) and a primer, a new DNA molecule, complementary to the single stranded DNA template, can be synthesized.

A number of DNA polymerases have been isolated from mesophilic microorganisms such as *E. coli*. A number of these mesophilic DNA polymerases have also been cloned. Lin *et al.* cloned and expressed T4 DNA polymerase in *E. coli* (*Proc. Natl. Acad. Sci. USA* 84:7000-7004 (1987)). Tabor *et al.* (U.S. Patent No. 4,795,699) describes a cloned T7 DNA polymerase, while Minkley *et al.* (*J. Biol. Chem.* 259:10386-10392 (1984)) and Chatterjee (U.S. Patent No. 5,047,342) described *E. coli* DNA polymerase I and the cloning of T5 DNA polymerase, respectively.

Although DNA polymerases from thermophiles are known, relatively little investigation has been done to isolate and even clone these enzymes. Chien *et al.*, *J. Bacteriol.* 127:1550-1557 (1976) describe a purification scheme for obtaining a polymerase from *Thermus aquaticus* (*Taq*). The resulting protein had a molecular weight of about 63,000 daltons by gel filtration analysis and 68,000 daltons by sucrose gradient centrifugation. Kaledin *et al.*, *Biokhimiya* 45:644-51 (1980) disclosed a purification procedure for isolating DNA polymerase from *T. aquaticus* YT1 strain. The purified enzyme was reported to be a 62,000 dalton monomeric protein. Gelfand *et al.* (U.S. Patent No. 4,889,818) cloned a gene encoding a thermostable DNA polymerase from *Thermus aquaticus*. The molecular weight of this protein was found to be about 86,000 to 90,000 daltons.

Simpson *et al.* purified and partially characterized a thermostable DNA polymerase from a *Thermotoga* species (*Biochem. Cell. Biol.* 86:1292-1296

(1990)). The purified DNA polymerase isolated by Simpson *et al.* exhibited a molecular weight of 85,000 daltons as determined by SDS-polyacrylamide gel electrophoresis and size-exclusion chromatography. The enzyme exhibited half-lives of 3 minutes at 95°C and 60 minutes at 50°C in the absence of substrate and its pH optimum was in the range of pH 7.5 to 8.0. Triton X-100 appeared to enhance the thermostability of this enzyme. The strain used to obtain the thermostable DNA polymerase described by Simpson *et al.* was *Thermotoga* species strain FjSS3-B.1 (Hussar *et al.*, *FEMS Microbiology Letters* 37:121-127 (1986)). Others have cloned and sequenced a thermostable DNA polymerase from *Thermotoga maritima* (U.S. Patent 5,374,553, which is expressly incorporated herein by reference).

Other DNA polymerases have been isolated from thermophilic bacteria including *Bacillus steraothermophilus* (Stenesh *et al.*, *Biochim. Biophys. Acta* 272:156-166 (1972); and Kaboev *et al.*, *J. Bacteriol.* 145:21-26 (1981)) and several archaeobacterial species (Rossi *et al.*, *System. Appl. Microbiol.* 7:337-341 (1986); Klimczak *et al.*, *Biochemistry* 25:4850-4855 (1986); and Elie *et al.*, *Eur. J. Biochem.* 178:619-626 (1989)). The most extensively purified archaeobacterial DNA polymerase had a reported half-life of 15 minutes at 87°C (Elie *et al.* (1989), *supra*). Innis *et al.*, In *PCR Protocol: A Guide To Methods and Amplification*. Academic Press, Inc., San Diego (1990) noted that there are several extreme thermophilic eubacteria and archaeobacteria that are capable of growth at very high temperatures (Bergquist *et al.*, *Biotech. Genet. Eng. Rev.* 5:199-244 (1987); and Kelly *et al.*, *Biotechnol. Prog.* 4:47-62 (1988)) and suggested that these organisms may contain very thermostable DNA polymerases.

In many of the known polymerases, the 5'-3' exonuclease activity is present in the N-terminal region of the polymerase. (Ollis, *et al.*, *Nature* 313:762-766 (1985); Freemont *et al.*, *Proteins* 1:66-73 (1986); Joyce, *Cur. Opin. Struct. Biol.* 1:123-129 (1991).) There are some amino acids, the mutation of which are thought to impair the 5'-3' exonuclease activity of *E. coli* DNA polymerase I. (Gutman & Minton, *Nucl. Acids Res.* 21:4406-4407 (1993).) These

amino acids include Tyr⁷⁷, Gly¹⁰³, Gly¹⁸⁴, and Gly¹⁹² in *E. coli* DNA polymerase I. It is known that the 5'-exonuclease domain is dispensable. The best known example is the Klenow fragment of *E. coli* polymerase I. The Klenow fragment is a natural proteolytic fragment devoid of 5'-exonuclease activity (Joyce *et al.*,
5 *J. Biol. Chem.* 257:1958-64 (1990).) Polymerases lacking this activity are useful for DNA sequencing.

Most DNA polymerases also contain a 3'→5' exonuclease activity. This exonuclease activity provides a proofreading ability to the DNA polymerase. A T5 DNA polymerase that lacks 3'→5' exonuclease activity is disclosed in U.S.
10 Patent No. 5,270,179. Polymerases lacking this activity are particularly useful for DNA sequencing.

The polymerase active site, including the dNTP binding domain is usually present at the carboxyl terminal region of the polymerase (Ollis *et al.*, *Nature* 313:762-766 (1985); Freemont *et al.*, *Proteins* 1:66-73 (1986)). It has been
15 shown that Phe⁷⁶² of *E. coli* polymerase I is one of the amino acids that directly interacts with the nucleotides (Joyce & Steitz, *Ann. Rev. Biochem.* 63:777-822 (1994); Astatke, *J. Biol. Chem.* 270:1945-54 (1995)). Converting this amino acid to a Tyr results in a mutant DNA polymerase that does not discriminate against dideoxynucleotides. See copending U.S. Application No. 08/525,087, of Deb K.
20 Chatterjee, filed September 8, 1995, entitled "Mutant DNA Polymerases and the Use Thereof," which is expressly incorporated herein by reference.

Thus, there exists a need in the art to develop more thermostable DNA polymerases. There also exists a need in the art to obtain wild type or mutant DNA polymerases that are devoid of exonuclease activities and are non-
25 discriminating against dideoxynucleotides.

Summary of the Invention

The present invention satisfies these needs in the art by providing additional DNA polymerases useful in molecular biology. Specifically, this invention includes a thermostable DNA polymerase. Preferably, the polymerase
5 has a molecular weight of about 100 kilodaltons. Specifically, the DNA polymerase of the invention is isolated from *Thermotoga*, and more specifically, the DNA polymerase is obtained from *Thermotoga neapolitana* (*Tne*) and *Thermotoga maritima* (*Tma*). The *Thermotoga* species preferred for isolating the DNA polymerase of the present invention was isolated from an African
10 continental solfataric spring (Windberger *et al.*, *Arch. Microbiol.* 151: 506-512, (1989)).

The *Thermotoga* DNA polymerases of the present invention are extremely thermostable, showing more than 50% of activity after being heated for 60 minutes at 90°C with or without detergent. Thus, the DNA polymerases of the
15 present invention is more thermostable than *Taq* DNA polymerase.

The present invention is also directed to cloning a gene encoding a *Thermotoga* DNA polymerase enzyme. DNA molecules containing the *Thermotoga* DNA polymerase genes, according to the present invention, can be transformed and expressed in a host cell to produce the DNA polymerase. Any
20 number of hosts may be used to express the *Thermotoga* DNA polymerase gene of the present invention; including prokaryotic and eukaryotic cells. Preferably, prokaryotic cells are used to express the DNA polymerase of the invention. The preferred prokaryotic host according to the present invention is *E. coli*.

The present invention also relates mutant thermostable DNA polymerases of the PolI type and DNA coding therefor, wherein there is amino acid change in the O-helix which renders the polymerase nondiscriminatory against ddNTPs in sequencing reactions. The O-helix is defined as RXXXKXXXFXXXYYX,
25 wherein X is any amino acid.

The present invention also relates to *Thermotoga* DNA polymerase mutants that lack exonuclease activity and/or which are nondiscriminatory against ddNTPs in sequencing reactions.

5 The present invention is also directed generally to DNA polymerases that have mutations that result in substantially reduced or missing 5'-3' exonuclease activity.

In particular, the invention relates to a *Thermotoga* DNA polymerase mutant which is modified at least one way selected from the group consisting of

- 10 (a) to reduce or eliminate the 3'-5' exonuclease activity of the polymerase;
- (b) to reduce or eliminate the 5'-3' exonuclease activity of the polymerase; and
- (c) to reduce or eliminate discriminatory behavior against a dideoxynucleotide.

15 The invention also relates to a method of producing a DNA polymerase, said method comprising:

- (a) culturing the host cell of the invention;
- (b) expressing said gene; and
- (c) isolating said DNA polymerase from said host cell.

20 The invention also relates to a method of synthesizing a double-stranded DNA molecule comprising:

- (a) hybridizing a primer to a first DNA molecule; and
- (b) incubating said DNA molecule of step (a) in the presence of one or more deoxy- or dideoxyribonucleoside triphosphates and the DNA polymerase of the invention, under conditions sufficient to synthesize a second DNA molecule complementary to all or a portion of said first DNA molecule. Such deoxy- and dideoxyribonucleoside triphosphates include dATP, dCTP, dGTP, dTTP, dITP, 7-deaza-dGTP, 7-deaza-dATP, dUTP, ddATP, ddCTP, ddGTP, ddITP, ddTTP, [α -S]dATP, [α -S]dTTP, [α -S]dGTP, and [α -S]dCTP.
- 25

-7-

The invention also relates to a method of sequencing a DNA molecule, comprising:

- (a) hybridizing a primer to a first DNA molecule;
- (b) contacting said DNA molecule of step (a) with
5 deoxyribonucleoside triphosphates, the DNA polymerase of the invention, and a terminator nucleotide;
- (c) incubating the mixture of step (b) under conditions sufficient to synthesize a random population of DNA molecules complementary to said first DNA molecule, wherein said synthesized DNA molecules are shorter in length
10 than said first DNA molecule and wherein said synthesized DNA molecules comprise a terminator nucleotide at their 3' termini; and
- (d) separating said synthesized DNA molecules by size so that at least a part of the nucleotide sequence of said first DNA molecule can be determined. Such terminator nucleotides include ddTTP, ddATP, ddGTP, ddITP or ddCTP.

15 The invention also relates to a method for amplifying a double stranded DNA molecule, comprising:

- (a) providing a first and second primer, wherein said first primer is complementary to a sequence at or near the 3'-termini of the first strand of said DNA molecule and said second primer is complementary to a sequence at or near
20 the 3'-termini of the second strand of said DNA molecule;
- (b) hybridizing said first primer to said first strand and said second primer to said second strand in the presence of the DNA polymerase of the invention, under conditions such that a third DNA molecule complementary to said first strand and a fourth DNA molecule complementary to said second strand
25 are synthesized;
- (c) denaturing said first and third strand, and said second and fourth strands; and
- (d) repeating steps (a) to (c) one or more times.

-8-

The invention also relates to a kit for sequencing a DNA molecule, comprising:

(a) a first container means comprising the DNA polymerase of the invention;

5 (b) a second container means comprising one or more dideoxyribonucleoside triphosphates; and

(c) a third container means comprising one or more deoxyribonucleoside triphosphates.

10 The invention also relates to a kit for amplifying a DNA molecule, comprising:

(a) a first container means comprising the DNA polymerase of the invention; and

(b) a second container means comprising one or more deoxyribonucleoside triphosphates.

15 The present invention also relates to a mutant DNA polymerase having substantially reduced or eliminated 5'-3' exonuclease activity, wherein at least one of the amino acids corresponding to Asp⁸, Glu¹¹², Asp¹¹⁴, Asp¹¹⁵, Asp¹³⁷, Asp¹³⁹, Gly¹⁰², Gly¹⁸⁷, or Gly¹⁹⁵ of *Tne* DNA polymerase has been mutated.

20 The present invention also relates to a method of producing a mutant DNA polymerase having substantially reduced or eliminated 5'-3' exonuclease activity, wherein at least one of the amino acids corresponding to Asp⁸, Glu¹¹², Asp¹¹⁴, Asp¹¹⁵, Asp¹³⁷, Asp¹³⁹, Gly¹⁰², Gly¹⁸⁷, or Gly¹⁹⁵ of *Tne* DNA polymerase has been mutated. comprising:

- 25 (a) culturing the host cell of the invention;
- (b) expressing the mutant DNA polymerase; and
- (c) isolating said mutant DNA polymerase.

Brief Description of the Figures

FIG. 1 demonstrates the heat stability of *Tne* DNA polymerase at 90°C over time. Partially purified DNA polymerase from the crude extract of *Thermotoga neapolitana* cells was used in the assay.

FIG. 2 shows the time-dependent DNA polymerase activity of *Tne* DNA polymerase isolated from an *E. coli* host containing the cloned *Tne* DNA polymerase gene.

FIG. 3 compares the ability of various DNA polymerases to incorporate radioactive dATP and [α S]dATP. *Tne* DNA polymerase is more effective at incorporating [α S]dATP than was *Taq* DNA polymerase.

FIG. 4 shows the restriction map of the approximate DNA fragment which contains the *Tne* DNA polymerase gene in pSport 1 and pUC19. This figure also shows the region containing the O-helix homologous sequences.

FIGS. 5A and 5B shows the nucleotide and deduced amino acid sequences, in all 3 reading frames, for the carboxyl terminal portion, including the O-helix region, of the *Thermotoga neapolitana* polymerase gene.

FIG. 6A schematically depicts the construction of plasmids pUC-*Tne* (3'-5') and pUC-*Tne* FY.

FIG. 6B schematically depicts the construction of plasmids pTrc *Tne*35 and pTrc*Tne* FY.

FIG. 7 schematically depicts the construction of plasmid pTrc*Tne*35 FY.

FIG. 8 schematically depicts the construction of plasmid pTTQ*Tne*5 FY and pTTQ*Tne*535FY.

FIG. 9 depicts a gel containing two sequencing reaction sets showing the efficient 35 S incorporation by *Tne* DNA polymerase of Example 12. Alkali-denatured pUC19 DNA was sequenced with *Tne* DNA polymerase in set A. M13 mp19(+) DNA was sequenced in set B.

FIG. 10 depicts a gel containing three sequencing reaction sets showing that the mutant *Tne* DNA polymerase of Example 12 generates clear sequence

-10-

from plasmids containing cDNAs with poly(dA) tails. Alkali-denatured plasmid DNAs containing cDNA inserts were sequenced using either *Tne* DNA polymerase (sets A and B), or Sequenase Ver 2.0 (set C).

5 FIG. 11 depicts a gel containing three sequencing reaction sets that compare the mutant *Tne* DNA polymerase of Example 12 (set A), Sequenase™ (set B) and *Taq* DNA polymerase (set C) generated sequences from a plasmid containing poly(dC).

10 FIG. 12 depicts a gel containing three sequencing reaction sets showing that the mutant *Tne* DNA polymerase of Example 12 (set A) produces ³⁵S-labeled sequence 3-fold stronger than Thermo Sequenase™ (set B) and without the uneven band intensities obtained with *Taq* DNA polymerase (set C).

15 FIG. 13 depicts a gel containing four sequencing reaction sets demonstrating that the mutant *Tne* DNA polymerase of Example 12 produces high quality sequences of *in vitro* amplified DNA (set A, *E. coli* β polI (~450bp); set B, *E. coli* rrsE (~350 bp); set C, *ori* from pSC101 (~1.5 kb); and set D, an exon from human HSINF gene (~750 bp).

20 FIGS. 14A and 14B depict gels containing three and four sequencing reaction sets, respectively, showing that the mutant *Tne* DNA polymerase of Example 12 provides superior sequence from double-stranded DNA clones containing poly(dA) or poly(dC) stretches. Fig. 14A, supercoiled plasmid DNAs containing inserts with homopolymers were cycle sequenced using the mutant *Tne* DNA polymerase (set A, RPA1; set B, elf (cap binding protein); and set C, a poly(dC)-tailed 5' RACE-derived insert). Fig. 14B, supercoiled plasmid DNAs containing inserts with homopolymers were cycled sequenced using *Taq* DNA
25 polymerase (set D), or SequiTherm™ (sets E-G) (set D, RPA; set E, RPA; set F, a poly(dC)-tailed 5' RACE-derived insert; and set G, elf).

FIG. 15 depicts a gel containing two sequencing reaction sets showing cycle sequencing using the mutant *Tne* DNA polymerase of Example 12 and ³²P end-labeled primer.

FIGS. 16A-16C and 16D-16F depict two sets of chromatograms showing comparison of the mutant *Tne* DNA polymerase of Example 12 (16A-16C) to AmpliTaq FS™ (16D-16F) in Fluorescent Dye Primer Sequencing.

5 FIGS. 17A-17C and 17D-17F depict chromatograms showing a comparison of the mutant *Tne* DNA polymerase of Example 12 (17A) to AmpliTaq FS™ (17B) in Fluorescent Dye Terminator Sequencing.

Detailed Description of the Preferred Embodiments

Definitions

10 In the description that follows, a number of terms used in recombinant DNA technology are extensively utilized. In order to provide a clearer and consistent understanding of the specification and claims, including the scope to be given such terms, the following definitions are provided.

15 **Cloning vector.** A plasmid, cosmid or phage DNA or other DNA molecule which is able to replicate autonomously in a host cell, and which is characterized by one or a small number of restriction endonuclease recognition sites at which such DNA sequences may be cut in a determinable fashion without loss of an essential biological function of the vector, and into which DNA may be spliced in order to bring about its replication and cloning. The cloning vector may further contain a marker suitable for use in the identification of cells transformed with the cloning vector. Markers, for example, are tetracycline resistance or ampicillin resistance.

20 **Expression vector.** A vector similar to a cloning vector but which is capable of enhancing the expression of a gene which has been cloned into it, after transformation into a host. The cloned gene is usually placed under the control of (i.e., operably linked to) certain control sequences such as promoter sequences.

25 **Recombinant host.** Any prokaryotic or eukaryotic or microorganism which contains the desired cloned genes in an expression vector, cloning vector

-12-

or any DNA molecule. The term "recombinant host" is also meant to include those host cells which have been genetically engineered to contain the desired gene on the host chromosome or genome.

5 **Host.** Any prokaryotic or eukaryotic microorganism that is the recipient of a replicable expression vector, cloning vector or any DNA molecule. The DNA molecule may contain, but is not limited to, a structural gene, a promoter and/or an origin of replication.

10 **Promoter.** A DNA sequence generally described as the 5' region of a gene, located proximal to the start codon. At the promoter region, transcription of an adjacent gene(s) is initiated.

Gene. A DNA sequence that contains information necessary for expression of a polypeptide or protein. It includes the promoter and the structural gene as well as other sequences involved in expression of the protein.

15 **Structural gene.** A DNA sequence that is transcribed into messenger RNA that is then translated into a sequence of amino acids characteristic of a specific polypeptide.

Operably linked. As used herein means that the promoter is positioned to control the initiation of expression of the polypeptide encoded by the structural gene.

20 **Expression.** Expression is the process by which a gene produces a polypeptide. It includes transcription of the gene into messenger RNA (mRNA) and the translation of such mRNA into polypeptide(s).

25 **Substantially Pure.** As used herein "substantially pure" means that the desired purified protein is essentially free from contaminating cellular contaminants which are associated with the desired protein in nature. Contaminating cellular components may include, but are not limited to, phosphatases, exonucleases, endonucleases or undesirable DNA polymerase enzymes.

-13-

Primer. As used herein "primer" refers to a single-stranded oligonucleotide that is extended by covalent bonding of nucleotide monomers during amplification or polymerization of a DNA molecule.

5 **Template.** The term "template" as used herein refers to a double-stranded or single-stranded DNA molecule which is to be amplified, synthesized or sequenced. In the case of a double-stranded DNA molecule, denaturation of its strands to form a first and a second strand is performed before these molecules may be amplified, synthesized or sequenced. A primer, complementary to a portion of a DNA template is hybridized under appropriate conditions and the
10 DNA polymerase of the invention may then synthesize a DNA molecule complementary to said template or a portion thereof. The newly synthesized DNA molecule, according to the invention, may be equal or shorter in length than the original DNA template. Mismatch incorporation during the synthesis or extension of the newly synthesized DNA molecule may result in one or a number
15 of mismatched base pairs. Thus, the synthesized DNA molecule need not be exactly complementary to the DNA template.

Incorporating. The term "incorporating" as used herein means becoming a part of a DNA molecule or primer.

20 **Amplification.** As used herein "amplification" refers to any *in vitro* method for increasing the number of copies of a nucleotide sequence with the use of a DNA polymerase. Nucleic acid amplification results in the incorporation of nucleotides into a DNA molecule or primer thereby forming a new DNA molecule complementary to a DNA template. The formed DNA molecule and its template can be used as templates to synthesize additional DNA molecules.
25 As used herein, one amplification reaction may consist of many rounds of DNA replication. DNA amplification reactions include, for example, polymerase chain reactions (PCR). One PCR reaction may consist of 30 to 100 "cycles" of denaturation and synthesis of a DNA molecule.

30 **Oligonucleotide.** "Oligonucleotide" refers to a synthetic or natural molecule comprising a covalently linked sequence of nucleotides which are

-14-

joined by a phosphodiester bond between the 3' position of the pentose of one nucleotide and the 5' position of the pentose of the adjacent nucleotide.

Nucleotide. As used herein "nucleotide" refers to a base-sugar-phosphate combination. Nucleotides are monomeric units of a nucleic acid sequence (DNA and RNA). The term nucleotide includes deoxyribonucleoside triphosphates such as dATP, dCTP, dITP, dUTP, dGTP, dTTP, or derivatives thereof. Such derivatives include, for example, [α S]dATP, 7-deaza-dGTP and 7-deaza-dATP. The term nucleotide as used herein also refers to dideoxyribonucleoside triphosphates (ddNTPs) and their derivatives. Illustrated examples of dideoxyribonucleoside triphosphates include, but are not limited to, ddATP, ddCTP, ddGTP, ddITP, and ddTTP. According to the present invention, a "nucleotide" may be unlabeled or detectably labeled by well known techniques. Detectable labels include, for example, radioactive isotopes, fluorescent labels, chemiluminescent labels, bioluminescent labels and enzyme labels.

Thermostable. As used herein "thermostable" refers to a DNA polymerase which is resistant to inactivation by heat. DNA polymerases synthesize the formation of a DNA molecule complementary to a single-stranded DNA template by extending a primer in the 5'-to-3' direction. This activity for mesophilic DNA polymerases may be inactivated by heat treatment. For example, T5 DNA polymerase activity is totally inactivated by exposing the enzyme to a temperature of 90°C for 30 seconds. As used herein, a thermostable DNA polymerase activity is more resistant to heat inactivation than a mesophilic DNA polymerase. However, a thermostable DNA polymerase does not mean to refer to an enzyme which is totally resistant to heat inactivation and thus heat treatment may reduce the DNA polymerase activity to some extent. A thermostable DNA polymerase typically will also have a higher optimum temperature than mesophilic DNA polymerases.

Hybridization. The terms "hybridization" and "hybridizing" refers to the pairing of two complementary single-stranded nucleic acid molecules (RNA and/or DNA) to give a double-stranded molecule. As used herein, two nucleic

-15-

acid molecules may be hybridized, although the base pairing is not completely complementary. Accordingly, mismatched bases do not prevent hybridization of two nucleic acid molecules provided that appropriate conditions, well known in the art, are used.

5 **3'-to-5' Exonuclease Activity.** "3'-to-5' exonuclease activity" is an enzymatic activity well known to the art. This activity is often associated with DNA polymerases, and is thought to be involved in a DNA replication "editing" or correction mechanism.

10 A "DNA polymerase substantially reduced in 3'-to-5' exonuclease activity" is defined herein as either (1) a mutated DNA polymerase that has about or less than 10%, or preferably about or less than 1%, of the 3'-to-5' exonuclease activity of the corresponding unmutated, wild-type enzyme, or (2) a DNA polymerase having a 3'-to-5' exonuclease specific activity which is less than about 1 unit/mg protein, or preferably about or less than 0.1 units/mg protein. A
15 unit of activity of 3'-to-5' exonuclease is defined as the amount of activity that solubilizes 10 nmoles of substrate ends in 60 min. at 37°C, assayed as described in the "BRL 1989 Catalogue & Reference Guide", page 5, with *HhaI* fragments of *lambda* DNA 3'-end labeled with [³H]dTTP by terminal deoxynucleotidyl transferase (TdT). Protein is measured by the method of Bradford, *Anal.*
20 *Biochem.* 72:248 (1976). As a means of comparison, natural, wild-type-T5-DNA polymerase (DNAP) or T5-DNAP encoded by pTTQ19-T5-2 has a specific activity of about 10 units/mg protein while the DNA polymerase encoded by pTTQ19-T5-2(Exo-) (U.S. 5,270,179) has a specific activity of about 0.0001 units/mg protein, or 0.001% of the specific activity of the unmodified
25 enzyme, a 10⁵-fold reduction.

5'-to-3' Exonuclease Activity. "5'-to-3' exonuclease activity" is also an enzymatic activity well known in the art. This activity is often associated with DNA polymerases, such as *E. coli* PolI and PolIII.

30 A "DNA polymerase substantially reduced in 5'-to-3' exonuclease activity" is defined herein as either (1) a mutated DNA polymerase that has about

or less than 10%, or preferably about or less than 1%, of the 5'-to-3' exonuclease activity of the corresponding unmutated, wild-type enzyme, or (2) a DNA polymerase having 5'-to-3' exonuclease specific activity which is less than about 1 unit/mg protein, or preferably about or less than 0.1 units/mg protein.

5 Both of the 3'-to-5' and 5'-to-3' exonuclease activities can be observed on sequencing gels. Active 5'-to-3' exonuclease activity will produce nonspecific ladders in a sequencing gel by removing nucleotides from the 5'-end of the growing primers. 3'-to-5' exonuclease activity can be measured by following the degradation of radiolabeled primers in a sequencing gel. Thus, the relative
10 amounts of these activities, e.g. by comparing wild-type and mutant polymerases, can be determined with no more than routine experimentation.

1. *Cloning and Expression of Thermotoga DNA Polymerases*

The *Thermotoga* DNA polymerase of the invention can be isolated from any strain of *Thermotoga* which produces a DNA polymerase. The preferred
15 strain to isolate the gene encoding *Thermotoga* DNA polymerase of the present invention is *Thermotoga neapolitana* (*Tne*) and *Thermotoga maritima* (*Tma*). The most preferred *Thermotoga neapolitana* for isolating the DNA polymerase of the invention was isolated from an African continental solfataric spring (Windberger *et al.*, *Arch. Microbiol.* 151:506-512 (1989) and may be obtained
20 from Deutsche Sammlung von Microorganismen und Zellkulturen GmbH (DSMZ; German Collection of Microorganisms and Cell Culture) Mascheroder Weg 1b D-38124 Braunschweig, Germany, as Deposit No. 5068 (deposited December 13, 1988).

To clone a gene encoding a *Thermotoga* DNA polymerase of the
25 invention, isolated DNA which contains the polymerase gene obtained from *Thermotoga* cells, is used to construct a recombinant DNA library in a vector. Any vector, well known in the art, can be used to clone the wild type or mutant *Thermotoga* DNA polymerase of the present invention. However, the vector used

-17-

must be compatible with the host in which the recombinant DNA library will be transformed.

Prokaryotic vectors for constructing the plasmid library include plasmids such as those capable of replication in *E. coli* such as, for example, pBR322, ColE1, pSC101, pUC-vectors (pUC18, pUC19, etc.: In: *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1982); and Sambrook *et al.*, In: *Molecular Cloning A Laboratory Manual* (2d ed.) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989)). *Bacillus* plasmids include pC194, pC221, pC217. etc. Such plasmids are disclosed by Glyczan, T. In: *The Molecular Biology Bacilli*, Academic Press, York (1982), 307-329. Suitable *Streptomyces* plasmids include pIJ101 (Kendall *et al.*, *J. Bacteriol* 169:4177-4183 (1987)). *Pseudomonas* plasmids are reviewed by John *et al.*, (*Rad. Insec. Dis.* 8:693-704 (1986)), and Igaki, (*Jpn. J. Bacteriol.* 33:729-742 (1978)). Broad-host range plasmids or cosmids, such as pCP13 (Darzins and Chakrababary, *J. Bacteriol.* 159:9-18, 1984) can also be used for the present invention. The preferred vectors for cloning the genes of the present invention are prokaryotic vectors. Preferably, pCP13 and pUC vectors are used to clone the genes of the present invention.

The preferred host for cloning the wild type or mutant DNA polymerase genes of the invention is a prokaryotic host. The most preferred prokaryotic host is *E. coli*. However, the wild type or mutant DNA polymerase genes of the present invention may be cloned in other prokaryotic hosts including, but not limited to, *Escherichia*, *Bacillus*, *Streptomyces*, *Pseudomonas*, *Salmonella*, *Serratia*, and *Proteus*. Bacterial hosts of particular interest include *E. coli* DH10B, which may be obtained from Life Technologies, Inc. (LTI) (Gaithersburg, MD).

Eukaryotic hosts for cloning and expression of the wild type or mutant DNA polymerases of the present invention include yeast, fungi, and mammalian cells. Expression of the desired DNA polymerase in such eukaryotic cells may require the use of eukaryotic regulatory regions which include eukaryotic

promoters. Cloning and expressing the wild type or mutant DNA polymerase gene of the invention in eukaryotic cells may be accomplished by well known techniques using well known eukaryotic vector systems.

Once a DNA library has been constructed in a particular vector, an appropriate host is transformed by well known techniques. Transformed colonies are plated at a density of approximately 200-300 colonies per petri dish. Colonies are then screened for the expression of a heat stable DNA polymerase by transferring transformed *E. coli* colonies to nitrocellulose membranes. After the transferred cells are grown on nitrocellulose (approximately 12 hours), the cells are lysed by standard techniques, and the membranes are then treated at 95°C for 5 minutes to inactivate the endogenous *E. coli* enzyme. Other temperatures may be used to inactivate the host polymerases depending on the host used and the temperature stability of the DNA polymerase to be cloned. Stable DNA polymerase activity is then detected by assaying for the presence of DNA polymerase activity using well known techniques. Sagner *et al.*, *Gene* 97:119-123 (1991), which is hereby incorporated by reference in its entirety. The gene encoding a DNA polymerase of the present invention can be cloned using the procedure described by Sagner *et al.*, *supra*.

The recombinant host containing the wild type gene encoding *Tne* DNA polymerase, *E. coli* DH10B (pUC-Tne), was deposited on September 30, 1994, with the Agricultural Research Culture Collection (NRRL), 1815 N. University Street, Peoria, IL 61604 USA as Deposit No. NRRL B-21338. The gene encoding *Tma* DNA polymerase has also been cloned and sequenced (U.S. Patent 5,374,553, which is expressly incorporated by reference in its entirety).

If the *Thermotoga* (e.g., *Tne* or *Tma*) DNA polymerase has 3'-to-5' exonuclease activity, this activity may be reduced, substantially reduced, or eliminated by mutating the DNA polymerase gene. Such mutations include point mutations, frame shift mutations, deletions and insertions. Preferably, the region of the gene encoding the 3'-to-5' exonuclease activity is mutated or deleted using

techniques well known in the art (Sambrook *et al.*, (1989) in: *Molecular Cloning, A Laboratory Manual (2nd Ed.)*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.).

5 The 3'-to-5' exonuclease activity can be reduced or impaired by creating site specific mutants within the 3'-5' exonuclease domain. *See infra*. In a specific embodiment of the invention Asp³²³ of *Tne* DNA polymerase (SEQ ID NO. 3) is changed to any amino acid, preferably to Ala³²³ to substantially reduce 3'-to-5' exonuclease activity. In another specific embodiment of the invention, Asp³²³ of *Tma* may be changed to any other amino acid, preferably to Ala to
10 substantially reduce 3'-to-5' exonuclease activity.

The 5'-3' exonuclease activity of the DNA polymerase can be reduced or eliminated by mutating the DNA polymerase gene. Such mutations include point mutations, frame shift mutations, deletions, and insertions. Preferably, the region of the gene encoding the 5'-3' exonuclease activity is deleted using
15 techniques well known in the art. In embodiments of this invention, any one of six conserved amino acids that are associated with the 5'-3' exonuclease activity can be mutated. Examples of these conserved amino acids with respect to *Tne* DNA polymerase include Asp⁸, Glu¹¹², Asp¹¹⁴, Asp¹¹⁵, Asp¹³⁷, and Asp¹³⁹. Other possible sites for mutation are: Gly¹⁰², Gly¹⁸⁷ and Gly¹⁹⁵.

20 The present invention is directed broadly to mutations of DNA polymerases that result in the reduction or elimination of 5'-3' exonuclease activity. Other particular mutations correspond to the following amino acids.

E. coli polI: Asp¹³, Glu¹¹³, Asp¹¹⁵, Asp¹¹⁶, Asp¹³⁸, and Asp¹⁴⁰.
Taq pol: Asp¹⁸, Glu¹¹⁷, Asp¹¹⁹, Asp¹²⁰, Asp¹⁴², and Asp¹⁴⁴.
25 *Tma* pol: Asp⁸, Glu¹¹², Asp¹¹⁴, Asp¹¹⁵, Asp¹³⁷, and Asp¹³⁹.

Amino acid residues of *Taq* DNA polymerase are as numbered in U.S. 5,079,352.

Amino acid residues of *Thermotoga maritima* (*Tma*) DNA polymerase are numbered as in U.S. Patent No. 5,374,553.

By comparison to the amino acid sequence of other DNA polymerases, the corresponding sites can easily be located and the DNA mutanigized to prepare a coding sequence for the corresponding DNA polymerase which lacks the 5'-3' exonuclease activity. Examples of other DNA polymerases that can be so mutated include:

Enzyme or source	Mutation positions
<i>Streptococcus pneumoniae</i>	Asp ¹⁰ , Glu ¹¹⁴ , Asp ¹¹⁶ , Asp ¹¹⁷ , Asp ¹³⁹ , Asp ¹⁴¹
<i>Thermus flavus</i>	Asp ¹⁷ , Glu ¹¹⁶ , Asp ¹¹⁸ , Asp ¹¹⁹ , Asp ¹⁴¹ , Asp ¹⁴³
<i>Thermus thermophilus</i>	Asp ¹⁸ , Glu ¹¹⁸ , Asp ¹²⁰ , Asp ¹²¹ , Asp ¹⁴³ , Asp ¹⁴⁵
<i>Deinococcus radiodurans</i>	Asp ¹⁸ , Glu ¹¹⁷ , Asp ¹¹⁹ , Asp ¹²⁰ , Asp ¹⁴² , Asp ¹⁴⁴
<i>Bacillus caldotenax</i>	Asp ⁹ , Glu ¹⁰⁹ , Asp ¹¹¹ , Asp ¹¹² , Asp ¹³⁴ , Asp ¹³⁶

Coordinates of *S. pneumoniae*, *T. flavus*, *D. radiodurans*, *B. caldotenax* were obtained from Gutman and Minton. Coordinates of *T. thermophilus* were obtained from International Patent No. WO 92/06200.

To abolish the 5'-3' exonuclease activity, amino acids are selected which have different properties. For example, an acidic amino acid such as Asp may be changed to a basic, neutral or polar but uncharged amino acid such as Lys, Arg, His (basic); Ala, Val, Leu, Ile, Pro, Met, Phe, Trp (neutral); or Gly, Ser, Thr, Cys, Tyr, Asn or Gln (polar but uncharged). Glu may be changed to Asp, Ala, Val, Leu, Ile, Pro, Met, Phe, Trp, Gly, Ser, Thr, Cys, Tyr, Asn or Gln. Specifically, the Ala substitution in the corresponding position is expected to abolish 5'-exo activity.

Preferably, oligonucleotide directed mutagenesis is used to create the mutant DNA polymerase which allows for all possible classes of base pair changes at any determined site along the encoding DNA molecule. In general, this technique involves annealing a oligonucleotide complementary (except for

one or more mismatches) to a single stranded nucleotide sequence coding for the DNA polymerase of interest. The mismatched oligonucleotide is then extended by DNA polymerase, generating a double stranded DNA molecule which contains the desired change in sequence on one strand. The changes in sequence can of course result in the deletion, substitution, or insertion of an amino acid. The double stranded polynucleotide can then be inserted into an appropriate expression vector, and a mutant polypeptide can thus be produced. The above-described oligonucleotide directed mutagenesis can of course be carried out via PCR.

In other embodiments, the entire 5'-3' exonuclease domain of the DNA polymerase can be deleted by proteolytic cleavage or by genetic engineering. For example, a unique *Sph*I restriction site can be used to obtain a clone devoid of nucleotides encoding the 219 amino terminal amino acids of *Tne* DNA polymerase. Examples of such a clone are pTTQTne535FY and pTTQTne5FY. Alternatively, less than the 219 amino terminal amino acids may be removed, for example, by treating the DNA coding for the *Tne* DNA polymerase with an exonuclease, isolating the fragments, ligating the fragments into a cloning vehicle, transfecting cells with the cloning vehicle, and screening the transformants for DNA polymerase activity and lack of 5'-3' exonuclease activity, with no more than routine experimentation.

Thermotoga DNA polymerase mutants can also be made to render the polymerase non-discriminating against non-natural nucleotides such as dideoxynucleotides. Changes within the O-helix of *Thermotoga* polymerases, such as other point mutations, deletions, and insertions, can be made to render the polymerase non-discriminating. By way of example, one *Tne* DNA polymerase mutant having this property substitutes a nonnatural amino acid such as Tyr for Phe at amino acid 67 as numbered in Figs. 5A and 5B, and 730 of SEQ ID NO:3.

The O-helix region is a 14 amino acid sequence corresponding to amino acids 722-735 of SEQ ID NO:3 or amino acids 59-72 as numbered in Figs 5A and 5B. The O-helix may be defined as RXXXXXXXFXXXYX, wherein X is any

amino acid. The most important amino acids in conferring discriminatory activity include Arg, Lys and Phe. Amino acids which may be substituted for Arg at positions 722 are selected independently from Asp, Glu, Ala, Val, Leu, Ile, Pro, Met, Phe, Trp, Gly, Ser, Thr, Cys, Tyr, Gln, Asn, Lys and His. Amino acids that may be substituted for Phe at position 730 include Lys, Arg, His, Asp, Glu, Ala, Val, Leu, Ile, Pro, Met, Trp, Gly, Ser, Thr, Cys, Tyr, Asn or Gln. Amino acids that may be substituted for Lys at position 726 of SEQ ID NO: 3 include Tyr, Arg, His, Asp, Glu, Ala, Val, Leu, Ile, Pro, Met, Trp, Gly, Ser, Thr, Cys, Phe, Asn or Gln. Preferred mutants include Tyr⁷³⁰, Ala⁷³⁰, Ser⁷³⁰ and Thr⁷³⁰. Such mutants may be prepared by well known methods of site directed mutagenesis as described herein. See also Example 10.

The corresponding mutants can also be prepared from *Tma* DNA polymerase, including Arg⁷²², Lys⁷²⁶ and Phe⁷³⁰. Most preferred mutants include Phe⁷³⁰ to Tyr⁷³⁰, Ser⁷³⁰, Thr⁷³⁰ and Ala⁷³⁰.

2. *Enhancing Expression of Thermotoga DNA Polymerase*

To optimize expression of the wild type or mutant *Thermotoga* DNA polymerases of the present invention, inducible or constitutive promoters are well known and may be used to express high levels of a polymerase structural gene in a recombinant host. Similarly, high copy number vectors, well known in the art, may be used to achieve high levels of expression. Vectors having an inducible high copy number may also be useful to enhance expression of *Thermotoga* DNA polymerase in a recombinant host.

To express the desired structural gene in a prokaryotic cell (such as, *E. coli*, *B. subtilis*, *Pseudomonas*, etc.), it is necessary to operably link the desired structural gene to a functional prokaryotic promoter. However, the natural *Thermotoga* promoter may function in prokaryotic hosts allowing expression of the polymerase gene. Thus, the natural *Thermotoga* promoter or other promoters may be used to express the DNA polymerase gene. Such other promoters may

-23-

be used to enhance expression and may either be constitutive or regulatable (i.e., inducible or derepressible) promoters. Examples of constitutive promoters include the *int* promoter of bacteriophage λ , and the *bla* promoter of the β -lactamase gene of pBR322. Examples of inducible prokaryotic promoters include the major right and left promoters of bacteriophage λ (P_R and P_L), *trp*, *recA*, *lacZ*, *lacI*, *tet*, *gal*, *trc*, and *tac* promoters of *E. coli*. The *B. subtilis* promoters include α -amylase (Ulmanen *et al.*, *J. Bacteriol* 162:176-182 (1985)) and *Bacillus* bacteriophage promoters (Gryczan. T., In: *The Molecular Biology Of Bacilli*, Academic Press, New York (1982)). *Streptomyces* promoters are described by Ward *et al.*, *Mol. Gen. Genet.* 203:468-478 (1986)). Prokaryotic promoters are also reviewed by Glick, *J. Ind. Microbiol.* 1:277-282 (1987); Cenatiempo, Y., *Biochimie* 68:505-516 (1986); and Gottesman, *Ann. Rev. Genet.* 18:415-442 (1984). Expression in a prokaryotic cell also requires the presence of a ribosomal binding site upstream of the gene-encoding sequence. Such ribosomal binding sites are disclosed, for example, by Gold *et al.*, *Ann. Rev. Microbiol.* 35:365-404 (1981).

To enhance the expression of *Thermotoga* (e.g., *The* and *Tma*) DNA polymerase in a eukaryotic cell, well known eukaryotic promoters and hosts may be used. Preferably, however, enhanced expression of *Thermotoga* DNA polymerase is accomplished in a prokaryotic host. The preferred prokaryotic host for overexpressing this enzyme is *E. coli*.

3. Isolation and Purification of *Thermotoga* DNA Polymerase

The enzyme(s) of the present invention (*Thermotoga* DNA polymerases and mutants thereof) is preferably produced by fermentation of the recombinant host containing and expressing the cloned DNA polymerase gene. However, the wild type and mutant DNA polymerases of the present invention may be isolated from any *Thermotoga* strain which produces the polymerase of the present invention. Fragments of the polymerase are also included in the present

-24-

invention. Such fragments include proteolytic fragments and fragments having polymerase activity.

Any nutrient that can be assimilated by *Thermotoga* or a host containing the cloned *Thermotoga* DNA polymerase gene may be added to the culture medium. Optimal culture conditions should be selected case by case according to the strain used and the composition of the culture medium. Antibiotics may also be added to the growth media to insure maintenance of vector DNA containing the desired gene to be expressed. Culture conditions for *Thermotoga neapolitana* have, for example, been described by Huber *et al.*, *Arch. Microbiol.* 144:324-333 (1986). Media formulations are also described in DSM or ATCC Catalogs and Sambrook *et al.*, In: *Molecular Cloning, a Laboratory Manual* (2nd ed.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).

Thermotoga and recombinant host cells producing the DNA polymerase of this invention can be separated from liquid culture, for example, by centrifugation. In general, the collected microbial cells are dispersed in a suitable buffer, and then broken down by ultrasonic treatment or by other well known procedures to allow extraction of the enzymes by the buffer solution. After removal of cell debris by ultracentrifugation or centrifugation, the DNA polymerase can be purified by standard protein purification techniques such as extraction, precipitation, chromatography, affinity chromatography, electrophoresis or the like. Assays to detect the presence of the DNA polymerase during purification are well known in the art and can be used during conventional biochemical purification methods to determine the presence of these enzymes.

4. Uses of *Thermotoga* DNA Polymerase

The wild type and mutant *Thermotoga* DNA polymerases (e.g., *Tma* and *Tne*) of the present invention may be used in well known DNA sequencing, DNA labeling, DNA amplification and cDNA synthesis reactions. *Thermotoga* DNA polymerase mutants devoid of or substantially reduced in 3'→5' exonuclease

-25-

activity, devoid of or substantially reduced in 5'→3' exonuclease activity, or containing one or mutations in the O-helix that make the enzyme nondiscriminatory for dNTPs and ddNTPs (e.g., a Phe⁷³⁰→Tyr⁷³⁰ mutation of SEQ ID NO: 3) are especially useful for DNA sequencing, DNA labeling, and DNA amplification reactions and cDNA synthesis. Moreover, *Thermotoga* DNA polymerase mutants containing two or more of these properties are also especially useful for DNA sequencing, DNA labeling, DNA amplification or cDNA synthesis reactions. As is well known, sequencing reactions (isothermal DNA sequencing and cycle sequencing of DNA) require the use of DNA polymerases. Dideoxy-mediated sequencing involves the use of a chain-termination technique which uses a specific polymer for extension by DNA polymerase, a base-specific chain terminator and the use of polyacrylamide gels to separate the newly synthesized chain-terminated DNA molecules by size so that at least a part of the nucleotide sequence of the original DNA molecule can be determined. Specifically, a DNA molecule is sequenced by using four separate DNA sequence reactions, each of which contains different base-specific terminators. For example, the first reaction will contain a G-specific terminator, the second reaction will contain a T-specific terminator, the third reaction will contain an A-specific terminator, and a fourth reaction may contain a C-specific terminator. Preferred terminator nucleotides include dideoxyribonucleoside triphosphates (ddNTPs) such as ddATP, ddTTP, ddGTP, ddITP and ddCTP. Analogs of dideoxyribonucleoside triphosphates may also be used and are well known in the art.

When sequencing a DNA molecule, ddNTPs lack a hydroxyl residue at the 3' position of the deoxyribose base and thus, although they can be incorporated by DNA polymerases into the growing DNA chain, the absence of the 3'-hydroxy residue prevents formation of the next phosphodiester bond resulting in termination of extension of the DNA molecule. Thus, when a small amount of one ddNTP is included in a sequencing reaction mixture, there is competition between extension of the chain and base-specific termination

resulting in a population of synthesized DNA molecules which are shorter in length than the DNA template to be sequenced. By using four different ddNTPs in four separate enzymatic reactions, populations of the synthesized DNA molecules can be separated by size so that at least a part of the nucleotide sequence of the original DNA molecule can be determined. DNA sequencing by dideoxy-nucleotides is well known and is described by Sambrook *et al.*, In: *Molecular Cloning, a Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989). As will be readily recognized, the *Thermotoga* DNA polymerases and mutants thereof of the present invention may be used in such sequencing reactions.

As is well known, detectably labeled nucleotides are typically included in sequencing reactions. Any number of labeled nucleotides can be used in sequencing (or labeling) reactions, including, but not limited to, radioactive isotopes, fluorescent labels, chemiluminescent labels, bioluminescent labels, and enzyme labels. It has been discovered that the wild type and mutant DNA polymerase of the present invention may be useful for incorporating α S nucleotides ($[\alpha$ S]dATP, $[\alpha$ S]dTTP, $[\alpha$ S]dCTP and $[\alpha$ S]dGTP) during sequencing (or labeling) reactions. For example, $[\alpha^{35}\text{S}]$ dATP, a commonly used detectably labeled nucleotide in sequencing reactions, is incorporated three times more efficiently with the *Tne* DNA polymerase of the present invention, than with *Taq* DNA polymerase. Thus, the enzyme of the present invention is particularly suited for sequencing or labeling DNA molecules with $[\alpha^{35}\text{S}]$ dNTPs.

Polymerase chain reaction (PCR), a well known DNA amplification technique, is a process by which DNA polymerase and deoxyribonucleoside triphosphates are used to amplify a target DNA template. In such PCR reactions, two primers, one complementary to the 3' termini (or near the 3'-termini) of the first strand of the DNA molecule to be amplified, and a second primer complementary to the 3' termini (or near the 3'-termini) of the second strand of the DNA molecule to be amplified, are hybridized to their respective DNA strands. After hybridization, DNA polymerase, in the presence of

deoxyribonucleoside triphosphates, allows the synthesis of a third DNA molecule complementary to the first strand and a fourth DNA molecule complementary to the second strand of the DNA molecule to be amplified. This synthesis results in two double stranded DNA molecules. Such double stranded DNA molecules may then be used as DNA templates for synthesis of additional DNA molecules by providing a DNA polymerase, primers, and deoxyribonucleoside triphosphates. As is well known, the additional synthesis is carried out by "cycling" the original reaction (with excess primers and deoxyribonucleoside triphosphates) allowing multiple denaturing and synthesis steps. Typically, denaturing of double stranded DNA molecules to form single stranded DNA templates is accomplished by high temperatures. The wild type and mutant *Thermotoga* DNA polymerases of the present invention are heat stable DNA polymerases, and thus will survive such thermal cycling during DNA amplification reactions. Thus, the wild type and mutant DNA polymerases of the invention are ideally suited for PCR reactions, particularly where high temperatures are used to denature the DNA molecules during amplification.

The *Thermotoga* DNA polymerase and mutants of the present invention (e.g. *Tne* and *Tma*) may also be used to prepare cDNA from mRNA templates. See, U.S. Patent Nos. 5,405,776 and 5,244,797, the disclosures of which are explicitly incorporated by reference herein. Thus, the invention also relates to a method of preparing cDNA from mRNA, comprising

(a) contacting mRNA with an oligo(dT) primer or other complementary primer to form a hybrid, and

(b) contacting said hybrid formed in step (a) with the *Thermotoga* DNA polymerase or mutant of the invention and the four dNTPs, whereby a cDNA-RNA hybrid is obtained.

If the reaction mixture is step (b) further comprises an appropriate oligonucleotide which is complementary to the cDNA being produced, it is also possible to obtain dsDNA following first strand synthesis. Thus, the invention

is also directed to a method of preparing dsDNA with the *Thermotoga* DNA polymerases and mutants thereof of the present invention.

5. Kits

The wild type and mutant *Thermotoga* DNA polymerases of the invention are suited for the preparation of a kit. Kits comprising the wild type or mutant DNA polymerase(s) may be used for detectably labeling DNA molecules, DNA sequencing, amplifying DNA molecules or cDNA synthesis by well known techniques, depending on the content of the kit. See U.S. Patent Nos. 4,962,020, 5,173,411, 4,795,699, 5,498,523, 5,405,776 and 5,244,797. Such kits may comprise a carrying means being compartmentalized to receive in close confinement one or more container means such as vials, test tubes and the like. Each of such container means comprises components or a mixture of components needed to perform DNA sequencing, DNA labeling, DNA amplification, or cDNA synthesis.

A kit for sequencing DNA may comprise a number of container means. A first container means may, for example, comprise a substantially purified sample of *Thermotoga* DNA polymerases or mutants thereof. A second container means may comprise one or a number of types of nucleotides needed to synthesize a DNA molecule complementary to DNA template. A third container means may comprise one or a number of different types of dideoxynucleoside triphosphates. A fourth container means may comprise pyrophosphatase. In addition to the above container means, additional container means may be included in the kit which comprise one or a number of DNA primers.

A kit used for amplifying DNA will comprise, for example, a first container means comprising a substantially pure mutant or wild type *Thermotoga* DNA polymerase of the invention and one or a number of additional container means which comprise a single type of nucleotide or mixtures of nucleotides. Various primers may or may not be included in a kit for amplifying DNA.

-29-

Kits for cDNA synthesis will comprise a first container means containing the wild type or mutant *Tne* DNA polymerase of the invention, a second container means will contain the four dNTPs and the third container means will contain oligo(dT) primer. See U.S. Patent Nos. 5,405,776 and 5,244,797. Since the
5 *Thermotoga* DNA polymerases of the present invention are also capable of preparing dsDNA, a fourth container means may contain an appropriate primer complementary to the first strand cDNA.

Of course, it is also possible to combine one or more of these reagents in a single tube. A detailed description of such formulations at working
10 concentrations is described in the patent application entitled "Stable Compositions for Nucleic Acid Amplification and Sequencing" filed on August 14, 1996, which is expressly incorporated by reference herein in its entirety.

When desired, the kit of the present invention may also include container means which comprise detectably labeled nucleotides which may be used during
15 the synthesis or sequencing of a DNA molecule. One of a number of labels may be used to detect such nucleotides. Illustrative labels include, but are not limited to, radioactive isotopes, fluorescent labels, chemiluminescent labels, bioluminescent labels and enzyme labels.

6. *Advantages of the Thermotoga DNA Polymerase*

Thermotoga DNA polymerases of the invention have distinct advantages
20 in DNA sequencing. For example, when using the *Tne* DNA polymerase mutants of the invention in single-extension sequencing, they generate strong, clear ³⁵S-labeled sequence, increase sequence signal to background ratio, generate ≥500 bases of sequence, reduce false stops in the sequencing ladder, and permit high
25 temperature sequencing reactions. The efficient ³⁵S incorporation by the *Tne* DNA polymerase mutants of the invention can reduce template requirement 10-fold, give sharper bands than ³²P, emit lower energy radiation than ³²P, and have a longer shelf life than ³²P. Further, the *Tne* polymerase mutants produce longer

-30-

sequence reads and gives more accurate sequence interpretation. In addition, the use of a 70°C reaction temperature with this thermophilic polymerase increases sequencing efficiency of structure-containing and GC-rich templates.

5 Compared to modified T7 DNA polymerase (Sequenase™), *The* DNA polymerase mutants allow improved sequencing efficiency of structure containing and GC-rich templates, are more forgiving in incubation times for labeling and extensions, and allow one to obtain full length sequence from one-tenth the amount of template. With regard to other polymerases, the *The* DNA polymerase mutants provide, under appropriate reaction conditions, more even band
10 intensities and give longer, more accurate sequence reads, exhibit no weak or absent "dropout" bands, exhibit improved sequencing efficiency of structure containing and GC-rich templates, exhibit no sequence artifacts from templates containing homopolymers, and provide for shorter film exposure and/or less template input due to the efficient ³⁵S-dNTP incorporation.

15 With regard to cycle sequencing, the *The* DNA polymerase mutants generate strong, clear ³⁵S-labeled sequence, they increase sequence signal to background ratio, generate ≥500 bases of sequence, reduce false stops in the sequencing ladder under appropriate conditions, and permit high temperature reactions. The *The* DNA polymerase mutants also allow for highly efficient ³⁵S
20 dATP incorporation and therefore shorter film exposures and/or less template input, give sharper bands than ³²P, give off lower energy radiation than ³²P and have a longer shelf life than ³²P. The *The* DNA polymerase mutants also produce longer sequence reads and give more accurate sequence interpretation. ³²P end labeling of primers generates data with less background from less pure DNA and
25 requires as little as 5 fmole (0.01 μg) of DNA.

With regard to cycle sequencing, compared to the mutant *Taq* DNA polymerase (ThermoSequenase™), the *The* DNA polymerase mutants generate three times stronger ³⁵S-labeled sequence without an extra 2 hour cycled labeling step, require no special primer design for ³⁵S labeling, and allow for sequencing
30 of PCR products directly using any primer. Compared to SequiTherm™, the

-31-

mutants of *Tne* DNA polymerase generate three times stronger ^{35}S -labeled sequence, give more even band intensities, gives longer and more accurate sequence reads, require less template and less primer, and give no sequence artifacts from templates containing homopolymers. Compared to various other polymerases (e.g. *Tth* DNA polymerase), the *Tne* DNA polymerase mutants under appropriate reaction conditions generate three times stronger ^{35}S -labeled sequence, give more even band intensities, give longer and more accurate sequence reads, give no weak or absent "dropout" bands, improve sequencing efficiency of structure-containing and GC-rich templates, and reduce false stops in sequencing ladders, including through homopolymer regions.

With regard to fluorescent sequencing, the mutants of *Tne* DNA polymerase readily accept dye primers and dye terminators, increase sequence signal to background ratio, produce fewer ambiguous calls, and generate ≥ 500 bases of sequence. The *Tne* DNA polymerase mutants also produce longer sequence read lengths, give more accurate sequence interpretation, and allow for quantitation of bases in heterologous mixtures. Since the *Tne* DNA polymerase mutants provide for good incorporation of dye terminators, such dye terminators can be reduced 500-fold. Further, increased signal improves bases calling, reduces cost and time to sequence, eliminates the need to remove excess dye terminators before gel loading, and produces more even band intensities. The efficient use of dye primers generates data with less background from impure DNA and requires as little as 0.6 μg of dsDNA (double-stranded DNA).

With regard to the use of Thermo SequenaseTM and AmpliTaq FSTM in fluorescent sequencing, the *Tne* DNA polymerase mutants provide more even band intensities in dye terminator sequencing and give comparable results with dye primers. With regard to SequiThermTM, the *Tne* DNA polymerase mutants give more even band intensities that give longer, more accurate sequencing reads with both dye terminators and dye primers, use 500-fold less dye terminators, eliminate post reaction clean up of dye terminators, require 10-fold less template, and allow for quantitation of bases in heterologous mixtures using dye primers.

-32-

With regard to the use of various other enzymes in fluorescent sequencing, such as AmpliTaq™ and AmpliTaqCS™ mutant *The* DNA polymerases under appropriate reaction conditions provide more even band intensities and more accurate sequence reads with both dye terminators and dye primers, give no weak or absent "dropout" bands, have lower background and fewer false stops, use 500-fold less dye terminators, eliminate post reaction clean up of dye terminators, require 10-fold less template, and allow for quantitation of bases in heterologous mixtures.

As shown in Fig. 3, *The* DNA polymerase incorporates α -thio dATP at three times the rate of *Taq* DNA polymerase. However, surprisingly, when α -thio dATP is used in place of dATP in sequencing reactions using [α -³⁵S]dATP and mutants of *The* DNA polymerase, the resulting sequencing band signal intensity is increased by approximately 8-10 fold. The weak signal seen when dATP is used reflects the mutant DNA polymerase's strong preference for incorporating dATP over α -thio dATP from a mixed pool. Attempts to improve signal intensity by merely decreasing the amount of dATP resulted in very poor quality sequence with many false stops. Parallel experiments with [α -³²P]dATP and low concentrations of dATP produced similar poor quality sequence, indicating that the nucleotide concentration imbalance was causing the enzyme to perform poorly. By using α -thio dATP mixed with [α -³⁵S]dATP, the four nucleotide concentrations kept constant without diminishing signal or sequence quality.

Having now generally described the invention, the same will be more readily understood through reference to the following Examples which are provided by way of illustration, and are not intended to be limiting of the present invention, unless specified.

Example 1: Bacterial Strains And Growth Conditions

Thermotoga neapolitana DSM No. 5068 was grown under anaerobic conditions as described in the DSM catalog (addition of resazurin, Na₂S, and sulfur granules while sparging the media with nitrogen) at 85°C in an oil bath from 12 to 24 hours. The cells were harvested by filtering the broth through Whatman #1 filter paper. The supernatant was collected in an ice bath and then centrifuged in a refrigerated centrifuge at 8,000 rpms for twenty minutes. The cell paste was stored at -70°C prior to total genomic DNA isolation.

E. coli strains were grown in 2X LB broth base (Lennox L broth base: GIBCO/BRL) medium. Transformed cells were incubated in SOC (2% tryptone, 0.5% yeast extract, yeast 10 mM NaCl, 2.5 mM KCl, 20mM glucose, 10mM MgCl₂, and 10mM MgSO₄ per liter) before plating. When appropriate antibiotic supplements were 20 mg/l tetracycline and 100 mg/l ampicillin. *E. coli* strain DH10B (Lorow *et al.*, *Focus* 12:19-20 (1990)) was used as host strain. Competent DH10B may be obtained from Life Technologies, Inc. (LTI) (Gaithersburg, MD).

Example 2: DNA Isolation

Thermotoga neapolitana chromosomal DNA was isolated from 1.1g of cells by suspending the cells in 2.5 ml TNE (50mM Tris-HCl, pH 8.0, 50mM NaCl, 10mM EDTA) and treated with 1% SDS for 10 minutes at 37°C. DNA was extracted with phenol by gently rocking the lysed cells overnight at 4°C. The next day, the lysed cells were extracted with chloroform:isoamyl alcohol. The resulting chromosomal DNA was further purified by centrifugation in a CsCl density gradient. Chromosomal DNA isolated from the density gradient was extracted three times with isopropanol and dialyzed overnight against a buffer containing 10 mM Tris-HCl (pH 8.0) and 1 mM EDTA (TE).

Example 3: Construction of Genomic Libraries

The chromosomal DNA isolated in Example 2 was used to construct a genomic library in the plasmid pCP13. Briefly, 10 tubes each containing 10 μ g of *Thermotoga neapolitana* chromosomal DNA was digested with 0.01 to 10 units of Sau3AI for 1 hour at 37°C. A portion of the digested DNA was tested in an agarose (1.2%) gel to determine the extent of digestion. Samples with less than 50% digestion were pooled, ethanol precipitated and dissolved in TE. 6.5 μ g of partially digested chromosomal DNA was ligated into 1.5 μ g of pCP13 cosmid which had been digested with *Bam*HI restriction endonuclease and dephosphorylated with calf intestinal alkaline phosphatase. Ligation of the partially digested *Thermotoga* DNA and *Bam*HI cleaved pCP13 was carried out with T4 DNA ligase at 22°C for 16 hours. After ligation, about 1 μ g of ligated DNA was packaged using λ -packaging extract (obtained from Life Technologies, Inc., Gaithersburg, MD). DH10B cells (Life Tech. Inc.) were then infected with 100 μ l of the packaged material. The infected cells were plated on tetracycline containing plates. Serial dilutions were made so that approximately 200 to 300 tetracycline resistant colonies were obtained per plate.

Example 4: Screening for Clones Expressing Thermotoga neapolitana DNA Polymerase

Identification of the *Thermotoga neapolitana* DNA polymerase gene of the invention was cloned using the method of Sagner *et al.*, *Gene* 97:119-123 (1991) which reference is herein incorporated in its entirety. Briefly, the *E. coli* tetracycline resistant colonies from Example 3 were transferred to nitrocellulose membranes and allowed to grow for 12 hours. The cells were then lysed with the fumes of chloroform:toluene (1:1) for 20 minutes and dried for 10 minutes at room temperature. The membranes were then treated at 95°C for 5 minutes to inactivate the endogenous *E. coli* enzymes. Surviving DNA polymerase activity

-35-

was detected by submerging the membranes in 15 ml of polymerase reaction mix (50 mM Tris-HCl (pH 8.8), 1 mM MgCl₂, 3 mM β -mercaptoethanol, 10 μ M dCTP, dGTP, dTTP, and 15 μ Ci of 3,000 Ci/mmol [α ³²P]dATP) for 30 minutes at 65°C.

5 Using autoradiography, three colonies were identified that expressed a *Thermotoga neapolitana* DNA polymerase. The cells were grown in liquid culture and the protein extract was made by sonication. The presence of the cloned thermostable polymerase was confirmed by treatment at 90°C followed by measurement of DNA polymerase activity at 72°C by incorporation of
10 radioactive deoxyribonucleoside triphosphates into acid insoluble DNA. One of the clones, expressing *Tne* DNA polymerase, contained a plasmid designated pCP13-32 and was used for further study.

Example 5: Subcloning of Tne DNA polymerase

15 Since the pCP13-32 clone expressing the *Tne* DNA polymerase gene contains about 25 kb of *T. neapolitana* DNA, subcloning a smaller fragment of the *Tne* polymerase gene was attempted. The molecular weight of the *Tne* DNA polymerase purified from *E. coli*/pCP13-32 was about 100 kd. Therefore, a 2.5-3.0 kb DNA fragment will be sufficient to code for full-length polymerase. A second round of *Sau*3A partial digestion similar to Example 3 was done using
20 pCP13-32 DNA. In this case, a 3.5 kb region was cut out from the agarose gel, purified by Gene Clean (BIO 101, La Jolla, CA) and ligated into plasmid pSport 1 (Life Technologies, Inc.) which had been linearized with *Bam*HI and dephosphorylated with calf intestinal alkaline phosphatase. After ligation, DH10B was transformed and colonies were tested for DNA polymerase activity
25 as described in Example 4. Several clones were identified that expressed *Tne* DNA polymerase. One of the clones (pSport-*Tne*) containing about 3 kb insert was further characterized. A restriction map of the DNA fragment is shown in

-36-

Fig. 4. Further, a 2.7 Kb *HindIII-SstI* fragment was subcloned into pUC19 to generate pUC19-*Tne*. *E. coli*/pUC19-*Tne* also produced *Tne* DNA polymerase.

The *Tne* polymerase clone was sequenced by methods known in the art. The nucleotide sequence obtained of the 5' end prior to the start ATG is shown in SEQ ID NO:1. The nucleotide sequence obtained which encodes carboxy-terminal region of the *Tne* polymerase is shown in Figs. 5A and 5B (SEQ ID NO:17). When SEQ ID NO:17 is translated it does not produce the entire amino acid sequence of the *Tne* polymerase due to frame shift errors generated during the determination of the nucleotide sequence. However, an amino acid sequence of the *Tne* polymerase was obtained by translating all three reading frames of SEQ ID NO:17, comparing these sequences with known polymerase amino acid sequences, and splicing the *Tne* polymerase sequence together to form the amino acid sequence set forth in SEQ ID NO:18. The complete nucleotide sequence coding for *Tne* is shown in SEQ ID NO:2 and the complete amino acid sequence is shown in SEQ ID NO:3.

SEQ ID NO:3 shows that the *Tne* sequence has an N-terminal methionine. It is not known with certainty whether the wild type *Tne* protein comprises an N-terminal methionine. It is possible to remove this N-terminal methionine according to methods well known to those of ordinary skill in the art, e.g. with a methionine amino peptidase.

Example 6: Purification of Thermotoga neapolitana DNA Polymerase from E. coli

Twelve grams of *E. coli* cells expressing cloned *Tne* DNA polymerase (DH10B/pSport-*Tne*) were lysed by sonication (four thirty-second bursts with a medium tip at the setting of nine with a Heat Systems Ultrasonics Inc., model 375 sonicator) in 20 ml of ice cold extraction buffer (50 mM Tris HCl (pH 7.4), 8% glycerol, 5 mM mercaptoethanol, 10 mM NaCl, 1 mM EDTA, 0.5 mM PMSF). The sonicated extract was heated at 80°C for 15 min. and then cooled in ice for

-37-

5 min. 50 mM KCl and PEI (0.4%) was added to remove nucleic acids. The extract was centrifuged for clarification. Ammonium sulfate was added to 60%, the pellet was collected by centrifugation and resuspended in 10 ml of column buffer (25 mM Tris-HCl (pH 7.4), 8% glycerol, 0.5% EDTA, 5mM 2-mercaptoethanol, 10 mM KCl). A Blue-Sepharose (Pharmacia) column, or preferably a Toso heparin (Tosohaas) column, was washed with 7 column volumes of column buffer and eluted with a 15 column volume gradient of buffer from 10mM to 2 M KCl. Fractions containing polymerase activity were pooled. The fractions were dialyzed against 20 volumes of column buffer. The pooled fractions were applied to a Toso650Q column (Tosohaas). The column was washed to baseline OD₂₈₀ and elution effected with a linear 10 column volume gradient of 25 mM Tris (pH 7.4), 8% glycerol, 0.5 mM EDTA, 10 mM KCl, 5 mM β -mercaptoethanol to the same buffer plus 650 mM KCl. Active fractions were pooled.

15 ***Example 7: Characterization of Purified The DNA Polymerase***

1. ***Determination of the Molecular Weight of Thermotoga neapolitana DNA Polymerase***

20 The molecular weight of 100 kilodaltons was determined by electrophoresis in a 12.5% SDS gel by the method of Laemmli, U.K., *Nature* (Lond.) 227:680-685 (1970). Proteins were detected by staining with Coomassie brilliant blue. A 10 kd protein ladder (Life Technologies, Inc.) was used as a standard.

-38-

2. *Method for Measuring Incorporation of [$\alpha^{35}\text{S}$]-dATP Relative to ^3H -dATP*

Incorporation of [αS]dATP was evaluated in a final volume of 500 μl of reaction mix, which was preincubated at 72°C for five minutes, containing either a [^3H]TTP nucleotide cocktail (100 μM each TTP, dATP, dCTP, dGTP with [^3H]TTP at 90.3 cpm/pmol), a nucleotide cocktail containing [αS]dATP as the only source of dATP (100 μM each [αS]dATP, dCTP, dGTP, TTP with [$\alpha^{35}\text{S}$]dATP at 235 cpm/pmol), or a mixed cocktail (50 μM [αS]dATP, 50 μM dATP, 100 μM TTP, 100 μM dCTP, 100 μM dGTP with [$^{35}\alpha\text{S}$] dATP at 118 cpm/pmol and [^3H]TTP at 45.2 cpm/pmol) and 50 mM bicine, pH 8.5, 30 mM MgCl_2 , 0.25 mg/ml activated salmon sperm DNA, 20% glycerol. The reaction was initiated by the addition of 0.3 units of *T. neapolitana* DNA polymerase or *T. aquaticus* DNA polymerase. At the times indicated a 25 μl aliquot was removed and quenched by addition of ice cold EDTA to a final concentration of 83 mM. 20 μl aliquots of the quenched reaction samples were spotted onto GF/C filters. Rates of incorporation were compared and expressed as a ratio of *T. neapolitana* to *T. aquaticus*. The incorporation of [$\alpha^{35}\text{S}$]dATP by *T. neapolitana* DNA polymerase was three-fold higher than that of *T. aquaticus* DNA polymerase.

Example 8: Reverse Transcriptase Activity

$(\text{A})_n:(\text{dT})_{12-18}$ is the synthetic template primer used most frequently to assay for reverse transcriptase activity of DNA polymerases. It is not specific for retroviral-like reverse transcriptase, however, being copied by many prokaryotic and eukaryotic DNA polymerases (Modak and Marcus, *J. Biol. Chem.* 252:11-19 (1977); Gerard *et al.*, *Biochem.* 13:1632-1641 (1974); Spadari and Weissbach, *J. Biol. Chem.* 249:5809-5815 (1974)). $(\text{A})_n:(\text{dT})_{12-18}$ is copied particularly well by cellular, replicative DNA polymerases in the presence of Mn^{++} , and much less

-39-

efficiently in the presence of Mg^{++} (Modak and Marcus, *J. Biol. Chem.* 252:11-19 (1977); Gerard *et al.*, *Biochem.* 13:1632-1641 (1974); Spadari and Weissbach, *J. Biol. Chem.* 249:5809-5815 (1974)). In contrast, most cellular, replicative DNA polymerases do not copy the synthetic template primer $(C)_n:(dG)_{12-18}$ efficiently in presence of either Mn^{++} or Mg^{++} , but retroviral reverse transcriptases do. Therefore, in testing for the reverse transcriptase activity of a DNA polymerase with synthetic template primers, the stringency of the test increases in the following manner from least to most stringent: $(A)_n:(dT)_{12-18}$ (Mn^{++}) < $(A)_n:(dT)_{12-18}$ (Mg^{++}) << $(C)_n:(dG)_{12-18}$ (Mn^{++}) < $(C)_n:(dG)_{12-18}$ (Mg^{++}).

The reverse transcriptase activity of *Tne* DNA polymerase was compared with *Thermus thermophilus* (*Tth*) DNA polymerase utilizing both $(A)_n:(dT)_{20}$ and $(C)_n:(dG)_{12-18}$. Reaction mixtures (50 μ l) with $(A)_n:(dT)_{20}$ contained 50 mM Tris-HCl (pH 8.4), 100 μ M $(A)_n$, 100 μ M $(dT)_{20}$, and either 40 mM KCl, 6 mM $MgCl_2$, 10 mM dithiothreitol, and 500 μ M [3H]dTTP (85 cpm/pmole), or 100 mM KCl, 1 mM $MnCl_2$, and 200 μ M [3H]dTTP (92 cpm/pmole). Reaction mixtures (50 μ l) with $(C)_n:(dG)_{12-18}$ contained 50 mM Tris-HCl (pH 8.4), 60 μ M $(C)_n$, 24 μ M $(dG)_{12-18}$, and either 50 mM KCl, 10 mM $MgCl_2$, 10 mM dithiothreitol, and 100 μ M [3H]dGTP (132 cpm/pmole), or 100 mM KCl, 0.5 mM $MnCl_2$, and 200 μ M [3H]dGTP (107 cpm/pmole). Reaction mixtures also contained either 2.5 units of the *Tth* DNA polymerase (Perkin-Elmer) or 2.5 units of the *Tne* DNA polymerase. Incubations were at 45°C for 10 min followed by 75°C for 20 min.

The table shows the results of determining the relative levels of incorporation of *Tne* and *Tth* DNA polymerase with $(A)_n:(dT)_{20}$ and $(C)_n:(dG)_{12-18}$ in the presence of Mg^{++} and Mn^{++} . *Tne* DNA polymerase appears to be a better reverse transcriptase than *Tth* DNA polymerase under reaction conditions more specific for reverse transcriptase, i.e., in the presence of $(A)_n:(dT)_{20}$ with Mg^{++} and $(C)_n:(dG)_{12-18}$ with Mn^{++} or Mg^{++} .

-40-

DNA Polymerase Activity of *Tth* and *Tne*
DNA Polymerase with (A)_n:(dT)₂₀ and (C)_n:(dG)₁₂₋₁₈

Enzyme	DNA Polymerase Activity (pMoles Complementary [³ H]dNTP Incorporated)			
	(A) _n :(dT) ₂₀ Mg ⁺⁺ Mn ⁺⁺		(C) _n :(dG) ₁₂₋₁₈ Mg ⁺⁺ Mn ⁺⁺	
<i>Tne</i>	161.8	188.7	0.6	4.2
<i>Tth</i>	44.8	541.8	0	0.9

Example 9: Construction of Thermotoga Neapolitana 3'-to-5'
Exonuclease Mutant

The amino acid sequence of portions of the *Tne* DNA polymerase was compared with other known DNA polymerases such as *E. coli* DNA polymerase 1, *Taq* DNA polymerase, T5 DNA polymerase, and T7 DNA polymerase to localize the regions of 3'-to-5' exonuclease activity, and the dNTP binding domains within the DNA polymerase. One of the 3'-to-5' exonuclease domains was determined based on the comparison of the amino acid sequences of various DNA polymerases (Blanco, L., et al. *Gene* 112: 139-144 (1992); Braithwaite and Ito, *Nucleic Acids Res.* 21: 787-802 (1993)) is as follows:

<i>Tne</i>	318	PSFALD*LETSS	328 (SEQ ID NO: 4)
Pol I	350	PVFAFDTETDS	360 (SEQ ID NO:5; Braithwaite and Ito, <i>supra</i>)
T5	133	GPVAFDSETSA	143 (SEQ ID NO:6; Braithwaite and Ito, <i>supra</i>)
T7	1	MIVSDIEANA	10 (SEQ ID NO:7; Braithwaite and Ito, <i>supra</i>).

-41-

As a first step to make the *Tne* DNA polymerase devoid of 3'→5' exonuclease activity, a 2kb *Sph* fragment from pSport-Tne was cloned into M13mp19 (LTI, Gaithersburg, MD). The recombinant clone was selected in *E. coli* DH5αF'IQ (LTI, Gaithersburg, MD). One of the clones with the proper insert was used to isolate uracilated single-stranded DNA by infecting *E. coli* CJ236 (Biorad, California) with the phage particle obtained from *E. coli* DH5αF'IQ. An oligonucleotide, GA CGT TTC AAG CGC TAG GGC AAA AGA (SEQ ID NO:8) was used to perform site directed mutagenesis. This site-directed mutagenesis converted Asp³²³ (indicated as * above) to Ala³²³. An *Eco*47III restriction site was created as part of this mutagenesis to facilitate screening of the mutant following mutagenesis. The mutagenesis was performed using a protocol as described in the Biorad manual (1987) except T7 DNA polymerase was used instead of T4 DNA polymerase (USB, Cleveland, OH). The mutant clones were screened for the *Eco*47III restriction site that was created in the mutagenic oligonucleotide. One of the mutants having the created *Eco*47III restriction site was used for further study. The mutation Asp³²³ to Ala³²³ has been confirmed by DNA sequencing.

To incorporate the 3'→5' exonuclease mutation in an expression vector, the mutant phage was digested with *Sph*I and *Hind*III. A 2 kb fragment containing the mutation was isolated. This fragment was cloned in pUC-Tne to replace the wild type fragment. See Figure 6A. The desired clone, pUC-Tne (3'→5'), was isolated. The presence of the mutant sequence was confirmed by the presence of the unique *Eco*47III site. The plasmid was then digested with *Sst*I and *Hind*III. The entire mutant polymerase gene (2.6 kb) was purified and cloned into *Sst*I and *Hind*III digested pTrc99 expression vector (Pharmacia, Sweden). The clones were selected in DH10B (LTI, Gaithersburg, MD). The resulting plasmid was designated pTrcTne35. See Figure 6B. This clone produced active heat stable DNA polymerase.

Example 10: Phenylalanine to Tyrosine Mutant

As discussed *supra*, the polymerase active site including the dNTP binding domain is usually present at the carboxyl terminal region of the polymerase. The sequence of the *Tne* polymerase gene suggests that the amino acids that presumably contact and interact with the dNTPs are present within the 694 bases starting at the internal *Bam*HI site. See Figure 4 and Figs. 5A and 5B. This conclusion is based on homology with a prototype polymerase *E. coli* DNA polymerase I. See Polisky et al., *J. Biol. Chem.* 265:14579-14591 (1990). The sequence of the carboxyl terminal portion of the polymerase gene is shown in Figs. 5A and 5B. Based upon this sequence, it is possible to compare the amino acid sequence within the O-helix for various polymerases. The complete sequence of the DNA polymerase is shown in SEQ ID NO:3. The corresponding O-helix region band on the sequence in Figs. 5A and 5B includes amino acids 59 to 72.

15	<i>Tne</i>	722	RRVGKMNFSIIYG	735	(SEQ ID NO:9)
	Pol I	754	RRSAKAINFGLIYG	767	(SEQ ID NO:10)
	T5	562	RQAAKAITFGILYG	575	(SEQ ID NO:11)
	T7	518	RDNAKTFIYGFLYG	531	(SEQ ID NO:12)
	<i>Taq</i>	659	RRAAKTINFGVLYG	672	(SEQ ID NO:13)

20 It was shown that by replacing the phenylalanine residue of *Taq* DNA polymerase, the polymerase becomes non-discriminating against non-natural nucleotides such as dideoxynucleotides. See application Serial No. 08/525,087 entitled "Mutant DNA Polymerases and Use Thereof" of Deb K. Chatterjee, filed September 8, 1995, specifically incorporated herein by reference. The mutation
25 was based on the assumption that T7 DNA polymerase contains a tyrosine residue in place of the phenylalanine, and T7 DNA polymerase is non-discriminating against dideoxynucleotides. The corresponding residue, Phe⁷⁶² of *E. coli* PolI is

-43-

an amino acid that directly interacts with nucleotides. (Joyce and Steitz, *Ann. Rev. Biochem.* 63:777-822 (1994); Astake, M.J., *J. Biol. Chem.* 270:1945-1954 (1995)). A similar mutant of *Tne* DNA polymerase was prepared.

In order to change Phe⁷³⁰ of the *Tne* polymerase to a Tyr⁷³⁰ as numbered
5 in SEQ ID NO:3, site directed mutagenesis was performed using the
oligonucleotide GTA TAT TAT AGA GTA GTT AAC CAT CTT TCC A. (SEQ
ID NO:14). As part of this oligonucleotide directed mutagenesis, a *HpaI*
restriction site was created in order to screen mutants easily. The same uracilated
single-stranded DNA and mutagenesis procedure described in Example 9 were
10 used for this mutagenesis. Following mutagenesis, the mutants were screened for
the *HpaI* site. Mutants with the desired *HpaI* site were used for further study.
The mutation has been confirmed by DNA sequencing.

The Phe⁷³⁰ to Tyr⁷³⁰ mutation was incorporated into pUC-*Tne* by replacing
the wild type *SphI* -*HindIII* fragment with the mutant fragment obtained from the
15 mutant phage DNA. The presence of the desired clone, pUC-TneFY, was
confirmed by the presence of the unique *HpaI* site, see Figure 6A. The entire
mutant polymerase gene was subcloned into pTrc99 as an *SstI*-*HindIII* fragment
as described above in DH10B. The resulting plasmid was designated
pTrcTneFY. (Figure 6B). The clone produced active heat stable polymerase.

20 **Example 11: 3'-to-5' Exonuclease and Phe⁷³⁰→Tyr⁷³⁰ Double Mutants**

In order to introduce the 3'-5' exonuclease mutation and the
Phe⁷³⁰→Tyr⁷³⁰ mutation in the same expression vector, pTrc99, it was necessary
to first reconstitute both mutations in the pUC-Tne clone. See Figure 7. Both the
25 pUC-Tne (3'-5') and the pUC-TneFY were digested with *Bam*HI. The digested
pUC-Tne (3'-5') was dephosphorylated to avoid recirculation in the following
ligations. The resulting fragments were purified on a 1% agarose gel. The largest
*Bam*HI fragment (4.4 kb) was purified from pUC-Tne (3'-5') digested DNA and

-44-

the smallest *Bam*HI fragment (0.8 kb) containing the Phe⁷³⁰→Tyr⁷³⁰ mutation was purified and ligated to generate pUC-Tne35FY. The proper orientation and the presence of both mutations in the same plasmid was confirmed by *Eco*47III, *Hpa*I, and *Sph*I-*Hind*III restriction digests. See Figure 7.

5 The entire polymerase containing both mutations was subcloned as a *Sst*I-*Hind*III fragment in pTrc99 to generate pTrcTne35FY in DH10B. The clone produced active heat stable polymerase.

***Example 12: 3'-to- 5' Exonuclease, 5'- to-3' Exonuclease,
and Phe⁷³⁰→Tyr⁷³⁰ Triple Mutants***

10 In most of the known polymerases, the 5'-to-3' exonuclease activity is present at the amino terminal region of the polymerase (Ollis, D.L., *et al.*, *Nature* 313, 762-766, 1985; Freemont, P.S., *et al.*, *Proteins* 1, 66-73, 1986; Joyce, C.M., *Curr. Opin. Struct. Biol.* 1: 123-129 (1991). There are some conserved amino acids that are implicated to be responsible for 5'-to-3' exonuclease activity

15 (Gutman and Minton, *Nucl. Acids Res.* 21, 4406-4407, 1993). *See supra*. It is known that 5'-to-3' exonuclease domain is dispensable. The best known example is the Klenow fragment of *E. coli* Pol I. The Klenow fragment is a natural proteolytic fragment devoid of 5'-to-3' exonuclease activity (Joyce, C.M., *et al.*, *J. Biol. Chem.* 257, 1958-1964, 1990). In order to generate an equivalent mutant

20 for *Tne* DNA polymerase devoid of 5'-to-3' exonuclease activity, the presence of a unique *Sph*I site present 680 bases from the *Sst*I site was exploited. pUC-Tne35FY was digested with *Hind*III, filled-in with Klenow fragment to generate a blunt-end, and digested with *Sph*I. The 1.9 kb fragment was cloned into an expression vector pTTQ19 (Stark, M.J.R., *Gene* 51, 255-267, 1987) at the

25 *Sph*I-*Sma*I sites and was introduced into DH10B. This cloning strategy generated an in-frame polymerase clone with an initiation codon for methionine from the vector. The resulting clone is devoid of 219 amino terminal amino acids of *Tne* DNA polymerase. This clone is designated as pTTQTne535FY. The clone

-45-

produced active heat stable polymerase. No exonuclease activity could be detected in the mutant polymerase as evidenced by lack of presence of unusual sequence ladders in the sequencing reaction. This particular mutant polymerase is highly suitable for DNA sequencing.

5 ***Example 13: 5'-to-3' Exonuclease Deletion and Phe⁷³⁰→Tyr⁷³⁰ Substitution Mutant***

10 In order to generate the 5'-3' exonuclease deletion mutant of the *Tne* DNA polymerase Phe⁷³⁰→Tyr⁷³⁰ mutant, the 1.8 kb *SphI-SpeI* fragment of pTTQTne535FY was replaced with the identical fragment of pUC-Tne FY. See Fig. 8. A resulting clone, pTTQTne5FY, produced active heat stable DNA polymerase. As measured by the rate of degradation of a labeled primer, this mutant has a modulated, low but detectable, 3'→5' exonuclease activity compared to wild type *Tne* DNA polymerase. M13/pUC Forward 23-Base Sequencing PrimerTM, obtainable from LTI, Gaithersburg, MD, was labeled at the 5' end with
15 [P³²] ATP and T4 kinase, also obtainable from LTI, Gaithersburg, MD, as described by the manufacturer. The reaction mixtures contained 20 units of either wild-type or mutant *Tne* DNA polymerase, 0.25 pmol of labeled primer, 20 mM tricine, pH 8.7, 85 mM potassium acetate, 1.2 mM magnesium acetate, and 8% glycerol. Incubation was carried out at 70°C. At various time points, 10 µl
20 aliquots were removed to 5 µl cycle sequencing stop solution and were resolved in a 6 % polyacrylamide sequencing gel followed by autoradiography. While the wild-type polymerase degraded the primer in 5 to 15 minutes, it took the mutant polymerase more than 60 minutes for the same amount of degradation of the primer. Preliminary results suggest that this mutant polymerase is able to amplify
25 more than 12 kb of genomic DNA when used in conjunction with *Taq* DNA polymerase. Thus, the mutant polymerase is suitable for large fragment PCR.

Example 14: Purification of the Mutant Polymerases

The purification of the mutant polymerases was done essentially as described in U.S. Patent Application Serial No. 08/370,190, filed January 9, 1995, entitled "Cloned DNA Polymerases for *Thermotoga neapolitana*," and as

5 in Example 6, *supra*, with minor modifications. Specifically, 5 to 10 grams of cells expressing cloned mutant *Tne* DNA polymerase were lysed by sonication with a Heat Systems Ultrasonic, Inc. Model 375 machine in a sonication buffer comprising 50 mM Tris-HCl (pH 7.4); 8% glycerol; 5 mM 2-mercaptoethanol, 10 mM NaCl, 1 mM EDTA, and 0.5 mM PMSF. The sonication sample was

10 heated at 75°C for 15 minutes. Following heat treatment, 200 mM NaCl and 0.4% PEI was added to remove nucleic acids. The extract was centrifuged for clarification. Ammonium sulfate was added to 48%, the pellet was resuspended in a column buffer consisting of 25 mM Tris-HCl (pH 7.4); 8% glycerol; 0.5% EDTA; 5 mM 2-mercaptoethanol; 10 mM KCl and loaded on a heparin agarose

15 (LTI) column. The column was washed with 10 column volumes using the loading buffer and eluted with a 10 column volume buffer gradient from 10 mM to 1 M KCl. Fractions containing polymerase activity were pooled and dialyzed in column buffer as above with the pH adjusted to 7.8. The dialyzed pool of fractions were loaded onto a MonoQ (Pharmacia) column. The column was

20 washed and eluted as described above for the heparin column. The active fractions are pooled and a unit assay was performed.

The unit assay reaction mixture contained 25 mM TAPS (pH 9.3), 2 mM MgCl₂, 50 mM KCl, 1 mM DTT, 0.2 mM dNTPs, 500 µg/ml DNase I treated salmon sperm DNA, 21 mCi/ml [α P³²] dCTP and various amounts of polymerase

25 in a final volume of 50 µl. After 10 minutes incubation at 70°C, 10 µl of 0.5 M EDTA was added to the tube. TCA precipitable counts were measured in GF/C filters using 40 µl of the reaction mixture.

Example 15: DNA Sequencing with the Mutant Polymerases

M13/pUC 23-base forward sequencing primer was ^{32}P -end-labeled for use in sequencing by incubating the following mixture at 37°C for 10 minutes: 60 mM Tris-HCl (pH 7.8), 10 mM MgCl_2 , 200 mM KCl, 0.2 μM primer, 0.4 μM (2 $\mu\text{Ci}/\mu\text{l}$) [γ - ^{32}P]ATP, 0.2 U/ μl T4 polynucleotide kinase. Labeling was terminated by incubating at 55°C for 5 minutes.

Four 10 μl base-specific sequencing reactions were set up for each test. The polymerase and the ddNTP concentrations were varied as follows:

Test	<i>Tne</i> DNA polymerase	[ddATP]	[ddCTP]	[ddGTP]	[ddTTP]
1	wild-type	0.4 mM	0.2 mM	0.04 mM	0.4 mM
2	TneFY	0.4 mM	0.2 mM	0.04 mM	0.4 mM
3	TneFY	0.04 mM	0.02 mM	0.004 mM	0.04 mM
4	TneFY	0.004 mM	0.002 mM	0.0004 mM	0.004 mM
5	Tne35FY	0.4 mM	0.2 mM	0.04 mM	0.4 mM
6	Tne35FY	0.04 mM	0.02 mM	0.004 mM	0.04 mM
7	Tne35FY	0.004 mM	0.002 mM	0.0004 mM	0.004 mM
8	Tne535FY	0.4 mM	0.2 mM	0.04 mM	0.4 mM
9	Tne535FY	0.04 mM	0.02 mM	0.004 mM	0.04 mM
10	Tne535FY	0.004 mM	0.002 mM	0.0004 mM	0.004 mM

Other components of the reaction were held constant: 1.1 nM pUC 18 DNA, 22 nM ^{32}P -end-labeled primer, 30 mM Tris-HCl (pH 9.0), 5 mM MgCl_2 , 50 mM KCl, 0.05% (w/v) W-1, 0.056 U/ μl DNA polymerase (see table), 20 μM dATP, 20 μM dCTP, 20 μM 7-deaza-dGTP, 20 μM dTTP. Samples were incubated in a thermal cycler at 95°C for 3 minutes, followed by 20 cycles of (30 seconds at 95°C, 30 seconds at 55°C, 60 seconds at 70°C) and 10 cycles of (30 seconds at 95°C, 60 seconds at 70°C). Reactions were terminated with 5 μl of stop solution (95% (v/v) formamide, 10 mM EDTA (pH 8.0), 0.1% (w/v) bromophenol blue,

-48-

0.1% (w/v) xylene cyanol and denatured for two minutes at 70°C. Three μ l aliquots were separated on a 6% TBE/urea sequencing gel. The dried gel was exposed to BioMAX-MR x-ray film for 16 hours.

Results

5 Cycle sequencing reactions using P^{32} end-labeled primers were prepared using wild-type *Tne* DNA polymerase and each of the three mutants, *TneFY*, *Tne35FY*, and *Tne535FY*. All four of the polymerases produced sequencing ladders. The *TneFY* mutant gave only a 9 base sequencing ladder when the *Taq* cycle sequencing reaction conditions were used. This is suggestive of premature
10 termination due to efficient ddNTP incorporation. Diluting the dideoxynucleotides by a factor of 100 extended the ladder to about 200 bases. The F-Y mutation in the *TneFY* polymerase therefore allowed dideoxynucleotides to be incorporated at a much higher frequency than for wild-type polymerase. The *Tne35FY* mutant demonstrated a similar ability to
15 incorporate dideoxynucleotides. In this case, the sequence extended to beyond 400 bases and the excess P^{32} end-labeled M13/pUC forward 23-Base sequencing primer band remained at the 23-base position in the ladder. The persistence of the 23-base primer band confirmed that the 3' - 5' exonuclease activity had been significantly reduced. The *Tne535FY* mutant performed similarly to the
20 *Tne35FY* mutant except that the signal intensity increased by at least fivefold. The background was very low and relative band intensities were extremely even, showing no patterns of sequence-dependent intensity variation.

Example 16: Generation of 5'-3' exonuclease mutant of full length *Tne* DNA polymerase

1. Identification of Two Amino Acids Responsible for 5'-3' Exonuclease Activity

5 *Tne* DNA polymerase contains three enzymatic activities similar to *E. coli* DNA polymerase I: 5'-3' DNA polymerase activity, 3'-5' exonuclease activity and 5'-3' exonuclease activity. This example is directed to the elimination of the 5'-3' exonuclease activity in full length *Tne* DNA polymerase. Gutman and Minton (*Nucleic Acids Res.* 1993, 21, 4406-4407) identified six (A-F) conserved 5'-3' exonuclease domains containing a total of 10 carboxylates in various DNA polymerases in the polI family. Seven out of 10 carboxylates (in domains A, D and E) have been implicated to be involved in divalent metal ions binding as judged from the crystal structure (Kim et al. *Nature*, 1995, 376, 612-616) of Taq DNA polymerase. However, there was no clear demonstration that these carboxylates are actually involved 5'-3' exonuclease activity. In order to find out the biochemical characteristics of some of these carboxylates, two of the aspartic acids in domains A and E were chosen for mutagenesis. The following aspartic acids in these two domains were identified:

20 *Tne* DNA polymerase: 5 F L F D⁸ G T 10 (domain A)
 Taq DNA polymerase: 15 L L V D¹⁸ G H 20

and

Tne DNA polymerase: 132 S L I T G D¹³⁷ K D M L 141 (domain E)
 Taq DNA polymerase: 137 R I L T A D¹⁴² K D L Y 146

-50-

2. *Isolation of Single Stranded DNA for Mutagenesis*

Single stranded DNA was isolated from pSportTne (see *infra*). pSportTne was introduced into DH5 α F'IQ (LTI, Gaithersburg, MD) by transformation. A single colony was grown in 2 ml Circle Grow (Bio 101, CA) medium with ampicillin at 37°C for 16 hrs. A 10 ml fresh media was inoculated with 0.1 ml of the culture and grown at 37°C until the A590 reached approximately 0.5. At that time, 0.1 ml of M13KO7 helper phage (1×10^{11} pfu/ml, LTI) was added to the culture. The infected culture was grown for 75 min. Kanamycin was then added at 50 μ g/ml, and the culture was grown overnight (16 hrs.). The culture was spun down. 9 ml of the supernatant was treated with 50 μ g each of RNaseA and DNaseI in the presence of 10 mM MgCl₂ for 30 min. at room temperature. To this mixture, 0.25 volume of a cocktail of 3M ammonium acetate plus 20% polyethylene glycol was added and incubated for 20 min. on ice to precipitate phage. The phage was recovered by centrifugation. The phage pellet was dissolved in 200 μ l of TE (10 mM Tris-HCl (pH 8) and 1 mM EDTA). The phage solution was extracted twice with equal volume of buffer saturated phenol (LTI, Gaithersburg, MD), twice with equal volume of phenol:chloroform:isoamyl alcohol mixture (25:24:1, LTI, Gaithersburg, MD) and finally, twice with chloroform: isoamyl alcohol (24:1). To the aqueous layer, 0.1 volume of 7.5 M ammonium acetate and 2.5 volume of ethanol were added and incubated for 15 min. at room temperature to precipitate single stranded DNA. The DNA was recovered by centrifugation and suspended in 200 μ l TE.

3. *Mutagenesis of D⁸ and D¹³⁷*

Two oligos were designed to mutagenize D⁸ and D¹³⁷ to alanine. The oligos are: 5' GTAGGCCAGGGCTGTGCCGGCAAAGAGAAATAGTC 3' (SEQ ID NO:15) (D8A) and 5' GAAGCATATCCTTGCGGCCGTTAT TATGAAAATC 3' (SEQ ID NO:16) (D137A). In the D8A oligo a NgoAIV

-51-

(bold underlined) and in the oligo D137A a *KasI* (bold underlined) site was created for easy identification of clones following mutagenesis. 200 pmol of each oligo was kinased according to the Muta-gene protocol (Bio-Rad, CA) using 5 units of T4 Kinase (LTI, Gaithersburg, MD). 200 ng of single stranded DNA was annealed with 2 pmol of oligo according to the Muta-gene protocol. The reaction volume was 10 μ l. Following the annealing step, complementary DNA synthesis and ligation was carried out using 5 units of wild-type T7 DNA polymerase (USB, Ohio) and 0.5 unit T4 ligase (LTI). 1 μ l of the reaction was used to transform a MutS *E. coli* (obtainable from Dr. Paul Modrich at the Duke University, NC) and selected in agar plates containing ampicillin. A control annealing and synthesis reaction was carried out without addition of any oligo to determine the background. There were 50-60 fold more colonies in the transformation plates with the oligos than without any oligo. Six colonies from each mutagenic oligo directed synthesis were grown and checked for respective restriction site (*NgoAIV* or *KasI*). For D8A (*NgoAIV*), 4 out of 6 generated two fragments (3 kb and 4.1 kb). Since pSportTne has an *NgoAIV* site near the fl intergenic region, the new *NgoAIV* site within the *Tne* DNA polymerase produced the expected fragments. The plasmid was designated as pSportTne*NgoAIV*. For D137A (*KasI*), 5 out of 6 clones produced two expected fragments of 1.1 kb and 6 kb in size. Since pSportTne has another *KasI* site, the newly created *KasI* site generated these two expected fragments. The plasmid was designated as pSportTne*KasI*. Both D8A and D137A mutations have been confirmed by DNA sequencing.

4. *Reconstruction of the Mutant Polymerase into Expression Vector*

During the course of expression of *Tne* DNA polymerase or mutant *Tne* DNA polymerase, a variety of clones were constructed. One such clone was designated as pTTQ *Tne* SeqS1. This plasmid was constructed as follows: first, similar to above mutagenesis technique glycine 195 was changed to an aspartic

-52-

acid in pSportTne. A mutation in the corresponding amino acid in *E. coli* DNA polymerase I (polA214, domain F) was found to have lost the 5'-3' exonuclease activity (Gutman and Minton, see above). An *SspI* site was created in the mutant polymerase. Second, a 650 bp *SstI-SphI* fragment containing the G195D mutation was subcloned in pUCTne35FY (see *infra*) to replace the wild type fragment. This plasmid was called pUCTne3022. Finally, the entire mutant *Tne* DNA polymerase was subcloned from pUCTne3022 into pTTQ18 as *SstI-HindIII* fragment to generate pTTQTneSeqS1. To introduce the mutation D8A or D137A in this expression vector, the 650 bp *SstI-SphI* was replaced with the same *SstI-SphI* fragment from pSportTneNgoAIV or pSportTneKasI. The plasmids were designated as pTTQTneNgo(D8A) and pTTQTneKas(D137A), respectively.

5. Confirmation of the Mutations by DNA Sequencing

DNA sequencing of both mutant polymerases confirmed the presence of the restriction site *NgoAIV* as well as the mutation D8A; and *KasI* site as well as the mutation D137A. Also confirmed by DNA sequencing was the presence of the mutation D323A and the *Eco47III* restriction site in the 3'-5' exonuclease region. In addition, confirmed by DNA sequencing was the F730Y mutation and the *HpaI* restriction site in the O-helix region of the mutant *Tne* DNA polymerase.

6. 5'-3' exonuclease Activity of the Mutant *Tne* DNA Polymerases

The full length mutant DNA polymerase was purified as described above. The 5'-3' exonuclease activity was determined as described in the LTI catalog. Briefly, 1 pmol of labeled (³²P) *HaeIII* digested λ DNA (LTI) was used for the assay. The buffer composition is: 25 mM Tris-HCl (pH 8.3), 5 mM MgCl₂, 50 mM NaCl, 0.01% gelatin. The reaction was initiated by the addition of 0, 2, 4, 6 and 10 units of either wild type or mutant *Tne* DNA polymerase in a 50 μ l

-53-

reaction. The reaction mix was incubated for 1 hr at 72°C. A 10 µl aliquot was subjected to PEI-cellulose thin layer chromatography and the label released was quantitated by liquid scintillation. In this assay, both D8A and D137A mutants showed less than 0.01% label release compared to the wild type *Tne* DNA polymerase. The result demonstrates that in both D8A and D137A mutants the 5'-3' exonuclease activity has been considerably diminished. Thus, it has been confirmed for the first time that these two aspartates are involved with the 5'-3' exonuclease activity.

7. *DNA Sequencing Characteristics of the Mutant DNA Polymerases*

Four separate base-specific reactions of the following composition were set up for each *Tne* polymerase mutant. 6.5 nM pUC 18, 111 nM M13/pUC 23 base forward sequencing primer, 30 mM Tris-HCl (pH 9.0), 5 mM MgCl₂, 10 mM NaCl, 10 mM DTT, 0.05% (w/v) W-1, 0.00185 U/µl inorganic pyrophosphatase, 0.37 µCi/µl (0.37 µM) [α -³⁵S]dATP, 16.7 µM α -thio-dATP, 16.7 µM dCTP, 16.7 µM 7-deaza-dGTP, 16.7 µM dTTP, and either 0.042 µM ddATP, 0.3 µM ddCTP, 0.255 µM ddGTP or 0.375 µM ddTTP. In these reactions, the concentrations of the various mutants were: 0.185 U/µl Tne535FY, or 0.170 U/µl D8A, or 0.185 U/µl D137A. Reaction volumes were 6 µl each. Sample tubes were incubated in an MJ Research DNA Engine thermal cycler at 95°C for 3 minutes, followed by 20 cycles of (30 seconds at 95°C, 30 seconds at 55°C and 60 seconds at 70°C), and 10 cycles of (30 seconds at 95°C and 60 seconds at 70°C). Reactions were terminated with 3 µl of stop solution (95% (v/v) formamide, 10 mM EDTA (pH 8.0), 0.1% (w/v) bromophenol blue, 0.1% (w/v) xylene cyanol) and denatured for two minutes at 70°C. Three µl aliquots were separated on a 6% TBE/urea sequencing gel. The dried gel was exposed to Kodak BioMAX x-ray film at room temperature approximately 18 hours.

The results of the sequencing data suggest that both D8A and D137A mutants of *Tne* DNA polymerase produced equivalent sequence ladders with

-54-

equal band intensity in all 4 lanes comparable to another *Tne* DNA polymerase where the 5'-exonuclease domain was deleted (Tne535FY). This result also suggests that both D8A and D137A mutants are devoid of 5'-exonuclease activity since no false bands are seen in the sequencing ladder, a characteristic of 5'-3' exonuclease containing DNA polymerase.

Example 17: Advantages of Tne DNA Polymerase Mutant in Sequencing Reactions

In this example, the *Tne* DNA polymerase of Example 12 was used which has the Phe⁷³⁰→Tyr⁷³⁰ mutation (making it non-discriminatory for dNTPs over ddNTPs), the Asp³²³→Ala³²³ mutation (which substantially reduces 3'-to-5' exonuclease activity), and the N-terminal 219 amino acid deletion mutation (which eliminates 5'-to-3' exonuclease activity).

Sequenase Ver 2.0™ is a modified T7 DNA polymerase sold by Amersham International plc, Little Chalfont, England.

Taq DNA polymerase was purchase from LTI, Gaithersburg, MD.

Thermo Sequenase™ is a *Taq* F→Y mutant containing a 5'-exonuclease deletion sold by Amersham International plc, Little Chalfont, England.

Ampli Taq FS™ is a *Taq* F→Y mutant believed to contain a Gly³⁷ mutation sold by Perkin Elmer ABI, Foster City, CA.

Sequithe™ is a thermophilic DNA polymerase sold by Epicenter, Madison, WI.

Methods

³⁵S cycle Sequencing with Tne DNA Polymerase

Four separate base-specific reactions of the following composition are set up for each template: 6.5 nM dsDNA, 111 nM primer, 30 mM Tris-HCl (pH 9.0),

-55-

5 mM MgCl₂, 10 mM NaCl, 10 mM DTT, 0.05% (w/v) W-1, 0.185 U/μL *Tne* DNA polymerase mutant, 0.00185 U/μl thermophilic inorganic pyrophosphatase, 0.37 μCi/μl (0.37 μM) [α-³⁵S]dATP, 16.7 μM α-thio-dATP, 16.7 μM dCTP, 16.7 μM 7-deaza-dGTP, 16.7 μM dTTP, and either 0.042 μM ddATP, 0.3 μM ddCTP, 0.255 μM ddGTP or 0.375 μM ddTTP. Reaction volumes are 6 μl each. Sample tubes are incubated in an MJ Research DNA Engine thermal cycler at 95°C for 3 minutes, followed by 20 cycles of (30 seconds at 95°C, 30 seconds at 55°C and 60 seconds at 70°C), and 10 cycles of (30 seconds at 95°C and 60 seconds at 70°C). Reactions are terminated with 3 μl of stop solution (95% (v/v) formamide, 10 mM EDTA (pH 8.0), 0.1% (w/v) bromophenol blue, 0.1% (w/v) xylene cyanol) and denatured for 2 minutes at 70°C. Three microliter aliquots are separated on a 6% TBE/urea sequencing gel. The dried gel is exposed to Kodak BioMAX x-ray film at room temperature for approximately 18 hours, unless otherwise specified.

15 ***³²P-end Labeled Primer Cycle Sequencing with *Tne* DNA Polymerase***

The sequencing primer is labeled by incubating the following 5 μl reaction for 10 minutes at 37°C: 60 mM Tris-HCl, 10 mM MgCl₂, 200 mM KCl, 0.6 μM primer, 0.4 μM (2 μCi/μl) [γ-³²P]ATP, 0.2 U/μl T4 polynucleotide kinase. The reaction is stopped by incubating 5 minutes at 55°C. Four separate base-specific reactions of the following composition are then set up for each template: 1.1 nM dsDNA, 67 nM ³²P-end-labeled primer, 30 mM Tris-HCl (pH 9.0), 5 mM MgCl₂, 50 mM KCl, 0.05% (w/v) W-1, 0.185 U/μl *Tne* DNA polymerase, 0.00185 U/μl thermophilic inorganic pyrophosphatase, 20 μM dATP, 20 μM dCTP, 20 μM 7-deaza-dGTP, 20 μM dTTP, and either 0.4 μM ddATP, 0.4 μM ddCTP, 0.4 μM ddGTP or 0.4 μM ddTTP. Reaction volumes are 10 μl each. Sample tubes are incubated in an MJ Research DNA Engine thermal cycler at 95°C for 3 minutes, followed by 20 cycles of (30 seconds at 95°C, 30 seconds at 55°C and 60 seconds at 70°C), and 10 cycles of (30 seconds at

-56-

95°C and 60 seconds at 70°C). Reactions are terminated with 5 µl of stop solution (95% (v/v) formamide, 10 mM EDTA (pH 8.0), 0.1% (w/v) bromophenol blue, 0.1% (w/v) xylene cyanol) and denatured for 2 minutes at 70°C. Three µl aliquots are separated on a 6% TBE/urea sequencing gel. The dried gel is exposed to Kodak BioMAX x-ray film at room temperature for approximately 18 hours, unless otherwise specified.

Single-extension Sequencing with Tne DNA Polymerase

This reaction requires either ssDNA or denatured dsDNA. The DNA is annealed to primer in a 10 µl volume by heating for five minutes at 50°C under the following reaction conditions: 150 nM dsDNA and 150 nM primer or 50 nM ssDNA and 50 nM primer with 60 mM Tris-HCl (pH 9.0), 60 mM KCl, 10 mM MgCl₂, 0.1% (w/v) W-1. The following labeling reaction is then incubated for five minutes at 50°C in a 15.5 µl volume: 10µl annealed DNA-primer 0.32 µCi/µl (0.32 µM) [α -³⁵S]dATP, 48.4 mM Tris HCl (pH 9.0), 48.4 mM KCl, 8.1 mM MgCl₂, 194 nM dCTP, 194 nM 7-deaza-dGTP, 194 nM dTTP, 6.5 nM DTT, 0.081% (w/v) W-1, 0.32 U/µl *Tne* DNA polymerase, 0.0032 U/µl thermophilic inorganic pyrophosphatase. The label mixture is then dispensed into four base-specific reaction tubes. Each tube contains a total reaction volume of 6 µl and is incubated for 5 minutes at 70°C under the following conditions: DNA-labeled primer 0.19 µCi/µl (0.19 µM) [α -³⁵S]dATP, 28 mM Tris-HCl (pH 9.0), 28 mM KCl, 4.7 mM MgCl₂, 42 µM dATP, 42 µM dCTP, 42 µM 7-deaza-dGTP, 42 µM dTTP, 3.8 mM DTT, 0.047% (w/v) W-1, 0.19 U/µl *Tne* DNA polymerase, 0.0019 U/µl thermophilic inorganic pyrophosphatase and either 0.83 µM ddATP, 0.83 µM ddCTP, 0.83 µM ddGTP or 0.83 µM ddTTP. Reactions are terminated by adding 4µl of stop solution (95% (v/v) formamide, 10 mM EDTA (pH 8.0), 0.1% (w/v) bromophenol blue, 0.1% (w/v) xylene cyanol) and denatured for 2 minutes at 70°C. Two µl aliquots are separated on a 6% TBE/urea sequencing gel. The

-57-

dried gel is exposed to Kodak BioMAX x-ray film at room temperature for approximately 2 hours, unless otherwise specified.

Fluorescent Dye Primer Sequencing with Tne DNA Polymerase

5 Four base-specific reactions are set up for each template. The A and C reaction volumes are 5 μ l and the G and T reaction volumes are 10 μ l. The composition of the reactions are as follows: 20 nM dsDNA or 10 nM ssDNA, with 30 mM Tris-HCl (pH 9.0), 30 mM KCl, 5 mM MgCl₂, 0.05% (w/v) W-1, 20 μ M dATP, 20 μ M dCTP, 20 μ M 7-deaza-dGTP, 20 μ M dTTP, 0.29 U/ μ l *Tne* DNA polymerase; 0.0029 U/ μ l thermophilic inorganic pyrophosphatase. Each
10 of the four tubes also contains a base-specific dye primer and ddNTP as follows:

A: 0.4 μ M JOE dye primer, 0.4 μ M ddATP

C: 0.4 μ M FAM dye primer, 0.4 μ M ddCTP

G: 0.4 μ M TAMRA dye primer, 0.4 μ M ddGTP

T: 0.4 μ M ROX dye primer, 0.4 μ M ddTTP

15 Sample tubes are incubated in a thermal cycler at 95°C for 3 minutes, followed by 20 cycles of (30 seconds at 95°C, 30 seconds at 55°C and 60 seconds at 70°C), and 10 cycles of (30 seconds at 95°C and 60 seconds at 70°C). Reactions are pooled, purified over a CentriSep spin column, and dried. The dried pellet is dissolved in 3 μ l of 83% formamide, 4.2 mM EDTA (pH 8.0) and heated for 2
20 minutes at 90°C just before loading the entire sample on a 4.75% polyacrylamide/TBE/urea gel in an ABI 373 Stretch machine. The gel is run at 32 watts for 14 hours.

Fluorescent Dye Terminator Sequencing with Tne DNA Polymerase

25 One 20 μ l reaction is set up for each template. The composition of the reaction is as follows: 12.5 nM dsDNA or 6.25 nM ssDNA, with 0.16 μ M primer, 30 mM Tris-HCl (pH 9.0), 30 mM KCl, 5 mM MgCl₂, 0.05% (w/v) W-

-58-

1, 0.6 mM dATP, 0.6 mM dCTP, 1.8 mM dITP, 0.6 mM dTTP, 0.5 U/ml *Tne* DNA polymerase, 0.005 U/ μ l thermophilic inorganic pyrophosphatase. The reaction also includes four base-specific dye terminators at a final concentration 16-fold lower than the original concentration supplied by ABI. The sample tube is incubated in a thermal cycler for 25 cycles of (30 seconds at 96°C, 15 seconds at 50°C and 4 minutes at 60°C). The reaction is purified over a CentriSep spin column, and dried. The dried pellet is dissolved in 3 μ l of 83% formamide, 4.2 mM EDTA (pH 8.0) and heated for 2 minutes at 90°C just before loading the entire sample on a 4.75% polyacrylamide/TBE/urea gel in an ABI 373 Stretch machine. The gel is run at 32 watts for 14 hours.

Results

Single-extension Sequencing

FIG. 9 shows that the efficient 35 S incorporation by *Tne* DNA polymerase mutant provides strong signals in single- and double-strand DNA sequencing. Alkali-denatured pUC19 DNA (1.5 pmol) was sequenced using single-extension sequencing with *Tne* DNA polymerase of Example 12 as described above (set A); film was exposed for only 2 hours. M13 mp19(+) DNA was used at one-tenth the normal amount of template (40 pmol) in the *Tne* DNA polymerase single-extension sequencing reactions as described (set B); film exposed for 20 hours. Since the *Tne* mutant produces such a strong signal, templates can be used more economically without sacrificing sequence quality.

FIG. 10 shows that the *Tne* DNA polymerase mutant generates clear sequence from plasmids containing cDNAs with poly(dA) tails. Alkali-denatured plasmid DNAs containing cDNA inserts (1.5 pmol) were sequenced using either the *Tne* DNA polymerase mutant in single-extension sequencing (sets A and B) as described, or Sequenase Ver 2.0™ (set C) following the standard kit protocol.

-59-

Set A, β -actin cDNA; set B, RPA1 cDNA (a replication protein); and set C, RPA2 cDNA (a replication protein).

FIG. 11 compares the *Tne* DNA polymerase mutant, Sequenase™ and *Taq* DNA polymerase generated sequences from a plasmid containing poly(dC). Plasmid DNA (1.5 pmol) containing a poly(dC)-tailed 5' RACE-derived insert was alkali denatured. The DNA was sequenced using *Tne* DNA polymerase mutant in single-extension sequencing (set A) as described, Sequenase Ver 2.0™ (set B) as described in the kit manual, and by *Taq* DNA polymerase (set C) following the recommended protocol in the TaqTrack kit (Promega, Madison, WI).

Cycle Sequencing.

FIG. 12 shows that the *Tne* DNA polymerase mutant in cycle sequencing produces ³⁵S-labeled sequence 3-fold stronger than Thermo Sequenase™ and without the 60-cycle labeling step. Plasmid DNA (0.5 μ g) containing a poly(dC)-tailed 5' RACE-derived insert was cycled sequenced using *Tne* DNA polymerase mutant (set A) as described; film exposure was 6 hours. Using Thermo Sequenase™ as described in the kit manual, the plasmid DNA (0.5 μ g) was labeled with ³⁵S by partial primer extension using an incubation of 60 cycles. This was followed by the standard cycle sequencing protocol in the presence of chain terminators (set B); film exposure was 18 hours. The plasmid DNA (0.5 μ g) was cycle sequenced using *Taq* DNA polymerase (set C) as described in the *fmol* kit manual; film exposure was 18 hours. Note, uneven band intensities in set C.

FIG. 13 shows that the *Tne* DNA polymerase mutant produces high quality sequences of *in vitro* amplified DNA. Templates were *in vitro* amplified directly from *E. coli* chromosomal DNA, from plasmid pSC101 and from human genomic DNA, purified by simple isopropanol precipitation and quantitated. DNAs (100 fmol) were cycle sequenced as described using the *Tne* DNA

-60-

polymerase mutant and one of the amplification primers. Set A, *E. coli* β polI (~450bp); set B, *E. coli* rrsE (~350 bp); set C, *ori* from pSC101 (~1.5 kb); and set D, an exon from human HSINF gene (~750 bp); amplified product sizes in parentheses. Note, these DNAs could not be sequenced using Thermo Sequenase™ because the primers did not meet the extra requirements for the labeling reaction.

FIGS. 14A and 14B show that the *Tne* DNA polymerase mutant provides superior sequence from double-stranded DNA clones containing poly(dA) or poly(dC) stretches. Fig. 14A, supercoiled plasmid DNAs containing inserts with homopolymers were cycle sequenced using the *Tne* DNA polymerase mutant as described; film exposure was 6 hours. Set A, RPA1; set B, elf (cap binding protein); and set C, a poly(dC)-tailed 5' RACE-derived insert.

FIG. 14B, supercoiled plasmid DNAs containing inserts with homopolymers were cycled sequenced using *Taq* DNA polymerase (set D) in the *fmol* kit manual, or SequiTherm™ (sets E-G) following the kit manual; film exposure was 18 hours. Set D, RPA; set E, RPA; set F, a poly(dC)-tailed 5' RACE-derived insert; and set G, elf. Note, the many false stops, especially in the homopolymer region.

FIG. 15 shows cycle sequencing using the *Tne* DNA polymerase mutant and ³²P end-labeled primer. A sequencing primer was first 5'-end labeled with ³²P using T4 kinase. A supercoiled plasmid DNA (50 fmol) was cycle sequenced using the *Tne* DNA polymerase mutant as described; film exposure was 18 hours. The left and right sets are aliquots of the same reaction, the right set loaded on the gel 45 minutes after the left.

Fluorescent Automated Sequencing

FIGS. 16A-16C and 16D-16F show a comparison of the *Tne* DNA polymerase mutant (16A-16C) to AmpliTaq FS™ (16D-16F) in fluorescent dye primer sequencing. pUC19 DNA was sequenced with dye primers (ABI, Foster

City, CA) using either the *Tne* DNA polymerase mutant or AmpliTaq FS™ as described.

FIGS. 17A-17C and 17D-17F show a comparison of the *Tne* DNA polymerase mutant (17A-17C) to AmpliTaq FS™ (17D-17F) in fluorescent dye terminator sequencing. pUC19 DNA was sequenced with dye terminators (ABI, Foster City, CA) using either the *Tne* DNA polymerase mutant or AmpliTaq FS™ as described. Note, greater evenness of peak heights with *Tne*.

These results demonstrate that the *Tne* DNA polymerase mutant gives unexpectedly better results in DNA sequencing compared to other DNA polymerases, whether they are similar mutants or not.

From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions without undue experimentation. All patents, patent applications and publications cited herein are incorporated by reference in their entirety.

-62-

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Life Technologies, Inc.
8717 Grovemont Circle
Gaithersburg, MD 20884-9980
APPLICANTS/INVENTORS: Chatterjee, Deb K.
Hughes, Jr., A. John
- (ii) TITLE OF INVENTION: Cloned DNA Polymerases from *Thermotoga*
and Mutants Thereof
- (iii) NUMBER OF SEQUENCES: 22
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
 - (B) STREET: 1100 New York Ave., N.W., Suite 600
 - (C) CITY: Washington
 - (D) STATE: DC
 - (E) COUNTRY: USA
 - (F) ZIP: 20005
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: To be assigned
 - (B) FILING DATE: Herewith
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 08/525,057
 - (B) FILING DATE: 08-SEP-1995
 - (C) CLASSIFICATION:
- (viii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 08/537,397
 - (B) FILING DATE: 02-OCT-1995
 - (C) CLASSIFICATION:
- (ix) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 08/537,400
 - (B) FILING DATE: 02-OCT-1995
 - (C) CLASSIFICATION:

-63-

(vii) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: 08/576,759
- (B) FILING DATE: 21-DEC-1995
- (C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: To be assigned
- (B) FILING DATE: 14-AUG-1996
- (C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: Esmond, Robert W.
- (B) REGISTRATION NUMBER: 32,893
- (C) REFERENCE/DOCKET NUMBER: 0942.280PC03

(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: 202-371-2600
- (B) TELEFAX: 202-371-2540

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: both

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GAGCTCACGG GGGATGCAGG AAA

23

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2682 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: both

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

ATGGCGAGAC TATTTCTCTT TGATGGCACA GCCCTGGCCT ACAGGGCATA TTACGCCCTC	60
GACAGATCCC TTTCCACATC CACAGGAATT CCAACGAACG CCGTCTATGG CGTTGCCAGG	120
ATGCTCGTTA AATTCATTAA GGAACACATT ATACCCGAAA AGGACTACGC GGCTGTGGCC	180
TTGACAAGA AGGCAGCGAC GTTCAGACAC AAAGTGTCTG TAAGCGACAA GGCGCAAAGG	240
CCAAAGACTC CGGCTCTTCT AGTTCAGCAG CTACCTTACA TCAAGCGGCT GATAGAAGCT	300
CTTGGTTTCA AAGTGCTGGA GCTGGAGGGA TACGAAGCAG ACGATATCAT CGCCACGCTT	360
GCAGTCAGGG CTGCACGTTT TTTGATGAGA TTTTCATTAA TAACCGGTGA CAAGGATATG	420
CTTCAACTTG TAAACGAGAA GATAAAGGTC TGGAGAATCG TCAAGGGGAT ATCGGATCTT	480
GAGCTTTACG ATTCGAAAAA GGTGAAAGAA AGATACGGTG TGAACCCACA TCAGATACCG	540
GATCTTCTAG CACTGACGGG AGACGACATA GACAACATTC CCGGTGTAAC GGAATAGGT	600
GAAAGACCG CTGTACAGCT TCTCGGCAAG TATAGAAATC TTGAATACAT TCTGGAGCAT	660
GCCCGTGAAC TCCCCAGAG AGTGAGAAAG GCTCTCTTGA GAGACAGGGA AGTTGCCATC	720
CTCAGTAAAA AACTTGCAAC TCTGGTGACG AACGCACCTG TTGAAGTGGA CTGGGAAGAG	780
ATGAAATACA GAGGATACGA CAAGAGAAAA CTACTTCCGA TATTGAAAGA ACTGGAGTTT	840
GCTTCCATCA TGAAGGAACT TCAACTGTAC GAAGAAGCAG AACCACCGG ATACGAAATC	900
GTGAAGGATC ATAAGACCTT CGAAGATCTC ATCGAAAAGC TGAAGGAGGT TCCATCTTTT	960
GCCCTGGACC TTGAAACGTC CTCCTTGGAC CCGTTCAACT GTGAGATAGT CGGCATCTCC	1020
GTGTCGTTCA AACCGAAAAC AGCTTATTAC ATTCCACTTC ATCACAGAAA CGCCCACAAT	1080
CTTGATGAAA CACTGGTGCT GTCGAAGTTG AAAGAGATCC TCGAAGACCC GTCTTCGAAG	1140
ATTGTGGGTC AGAACCTGAA GTACGACTAC AAGGTTCTTA TGGTAAAGGG TATATCGCCA	1200
GTTTATCCGC ATTTTGACAC GATGATAGCT GCATATTTGC TGGAGCCAAA CGAGAAAAAA	1260
TTCAATCTCG AAGATCTGTC TTTGAAATTT CTCGGATACA AAATGACGTC TTATCAGGAA	1320
CTGATGTCGT TTTCTCACC ACTTTTTGGT TTCAGCTTTG CGGATGTTCC GGTAGACAAG	1380
GCTGCCGAAT ACTCCTGCGA GGATGCAGAC ATCACTTATA GGCTCTACAA GATACTCAGC	1440
ATGAAGCTCC ATGAAGCGGA ACTTGAGAAC GTCTTCTACA GGATAGAGAT GCCGTTGGTG	1500
AACGTCTTGG CACGAATGGA ATTCAACTGG GTGTATGTTG ACACAGAATT CCTGAAAAAG	1560
CTCTCGGAGG AGTACGGCAA AAAGCTCGAG GAACTGGCCG AAAAAATCTA CCAGATAGCA	1620

-65-

```

GGTGAGCCCT TCAACATCAA TTCTCCAAAA CAGGTTTCAA ACATCCTTTT TGAGAAGCTG      1680
GGAATAAAAC CCCGTGGAAA AACGACAAAA ACAGGAGATT ACTCTACCAG GATAGAGGTG      1740
TTGGAAGAGA TAGCGAATGA GCACGAGATA GTACCCCTCA TTCTCGAGTT CAGAAAGATC      1800
CTGAAACTGA AATCGACCTA CATAGACACC CTTCCGAAAC TTGTGAACCC GAAAACCGGA      1860
AGATTTTCATG CATCTTTCCA CCAGACGGGT ACCGCCACTG GCAGGTTGAG TAGCAGTGAT      1920
CCAAATCTTC AGAATCTTCC GACAAAGAGC GAAGAGGGAA AAGAAATTAG AAAAGCGATT      1980
GTGCCCCAGG ATCCAGACTG GTGGATCGTC AGTGCGGATT ATTCCCAAAT AGAACTCAGA      2040
ATCCTCGCTC ATCTCAGTGG TGATGAGAAC CTTGTGAAGG CCTTCGAGGA GGGCATCGAT      2100
GTGCACACCT TGAATGCCTC CAGGATCTAC AACGTAAAGC CAGAAGAAGT GAACGAAGAA      2160
ATGCGACGGG TTGGAAAGAT GGTGAACCTC TCTATAATAT ACGGTGTCAC ACCGTACGGT      2220
CTTTCTGTGA GACTTGGAAT ACCGGTTAAA GAAGCAGAAA AGATGATTAT CAGCTATTTC      2280
ACACTGTATC CAAAGGTGCG AAGCTACATC CAGCAGGTTG TTGCAGAGGC AAAAGAGAAG      2340
GGCTACGTCA GGACTCTCTT TGGAAGAAAA AGAGATATTC CCCAGCTCAT GGCAAGGGAC      2400
AAGAACACCC AGTCCGAAGG CGAAAGAATC GCGATAAACA CCCCATTCA GGGAACTGCG      2460
GCAGATATAA TAAATTTGGC TATGATAGAT ATAGACGAGG AGCTGAGAAA AAGAAACATG      2520
AAATCCAGAA TGATCATTCA GGTTCATGAC GAACTGGTCT TCGAGGTTCC CGATGAGGAA      2580
AAAGAAGAAC TAGTTGATCT GGTGAAGAAC AAAATGACAA ATGTGGTGAA ACTCTCTGTG      2640
CCTCTTGAGG TTGACATAAG CATCGGAAAA AGCTGGTCTT GA                          2682

```

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 893 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```

Met Ala Arg Leu Phe Leu Phe Asp Gly Thr Ala Leu Ala Tyr Arg Ala
1           5           10           15

```

-66-

Tyr Tyr Ala Leu Asp Arg Ser Leu Ser Thr Ser Thr Gly Ile Pro Thr
 20 25 30
 Asn Ala Val Tyr Gly Val Ala Arg Met Leu Val Lys Phe Ile Lys Glu
 35 40 45
 His Ile Ile Pro Glu Lys Asp Tyr Ala Ala Val Ala Phe Asp Lys Lys
 50 55 60
 Ala Ala Thr Phe Arg His Lys Leu Leu Val Ser Asp Lys Ala Gln Arg
 65 70 75 80
 Pro Lys Thr Pro Ala Leu Leu Val Gln Gln Leu Pro Tyr Ile Lys Arg
 85 90 95
 Leu Ile Glu Ala Leu Gly Phe Lys Val Leu Glu Leu Glu Gly Tyr Glu
 100 105 110
 Ala Asp Asp Ile Ile Ala Thr Leu Ala Val Arg Ala Ala Arg Phe Leu
 115 120 125
 Met Arg Phe Ser Leu Ile Thr Gly Asp Lys Asp Met Leu Gln Leu Val
 130 135 140
 Asn Glu Lys Ile Lys Val Trp Arg Ile Val Lys Gly Ile Ser Asp Leu
 145 150 155 160
 Glu Leu Tyr Asp Ser Lys Lys Val Lys Glu Arg Tyr Gly Val Glu Pro
 165 170 175
 His Gln Ile Pro Asp Leu Leu Ala Leu Thr Gly Asp Asp Ile Asp Asn
 180 185 190
 Ile Pro Gly Val Thr Gly Ile Gly Glu Lys Thr Ala Val Gln Leu Leu
 195 200 205
 Gly Lys Tyr Arg Asn Leu Glu Tyr Ile Leu Glu His Ala Arg Glu Leu
 210 215 220
 Pro Gln Arg Val Arg Lys Ala Leu Leu Arg Asp Arg Glu Val Ala Ile
 225 230 235 240
 Leu Ser Lys Lys Leu Ala Thr Leu Val Thr Asn Ala Pro Val Glu Val
 245 250 255
 Asp Trp Glu Glu Met Lys Tyr Arg Gly Tyr Asp Lys Arg Lys Leu Leu
 260 265 270
 Pro Ile Leu Lys Glu Leu Glu Phe Ala Ser Ile Met Lys Glu Leu Gln
 275 280 285
 Leu Tyr Glu Glu Ala Glu Pro Thr Gly Tyr Glu Ile Val Lys Asp His
 290 295 300

-67-

Lys Thr Phe Glu Asp Leu Ile Glu Lys Leu Lys Glu Val Pro Ser Phe
 305 310 315 320
 Ala Leu Asp Leu Glu Thr Ser Ser Leu Asp Pro Phe Asn Cys Glu Ile
 325 330 335
 Val Gly Ile Ser Val Ser Phe Lys Pro Lys Thr Ala Tyr Tyr Ile Pro
 340 345 350
 Leu His His Arg Asn Ala His Asn Leu Asp Glu Thr Leu Val Leu Ser
 355 360 365
 Lys Leu Lys Glu Ile Leu Glu Asp Pro Ser Ser Lys Ile Val Gly Gln
 370 375 380
 Asn Leu Lys Tyr Asp Tyr Lys Val Leu Met Val Lys Gly Ile Ser Pro
 385 390 395 400
 Val Tyr Pro His Phe Asp Thr Met Ile Ala Ala Tyr Leu Leu Glu Pro
 405 410 415
 Asn Glu Lys Lys Phe Asn Leu Glu Asp Leu Ser Leu Lys Phe Leu Gly
 420 425 430
 Tyr Lys Met Thr Ser Tyr Gln Glu Leu Met Ser Phe Ser Ser Pro Leu
 435 440 445
 Phe Gly Phe Ser Phe Ala Asp Val Pro Val Asp Lys Ala Ala Glu Tyr
 450 455 460
 Ser Cys Glu Asp Ala Asp Ile Thr Tyr Arg Leu Tyr Lys Ile Leu Ser
 465 470 475 480
 Met Lys Leu His Glu Ala Glu Leu Glu Asn Val Phe Tyr Arg Ile Glu
 485 490 495
 Met Pro Leu Val Asn Val Leu Ala Arg Met Glu Phe Asn Trp Val Tyr
 500 505 510
 Val Asp Thr Glu Phe Leu Lys Lys Leu Ser Glu Glu Tyr Gly Lys Lys
 515 520 525
 Leu Glu Glu Leu Ala Glu Lys Ile Tyr Gln Ile Ala Gly Glu Pro Phe
 530 535 540
 Asn Ile Asn Ser Pro Lys Gln Val Ser Asn Ile Leu Phe Glu Lys Leu
 545 550 555 560
 Gly Ile Lys Pro Arg Gly Lys Thr Thr Lys Thr Gly Asp Tyr Ser Thr
 565 570 575
 Arg Ile Glu Val Leu Glu Glu Ile Ala Asn Glu His Glu Ile Val Pro
 580 585 590

-68-

Leu Ile Leu Glu Phe Arg Lys Ile Leu Lys Leu Lys Ser Thr Tyr Ile
 595 600 605
 Asp Thr Leu Pro Lys Leu Val Asn Pro Lys Thr Gly Arg Phe His Ala
 610 615 620
 Ser Phe His Gln Thr Gly Thr Ala Thr Gly Arg Leu Ser Ser Ser Asp
 625 630 635 640
 Pro Asn Leu Gln Asn Leu Pro Thr Lys Ser Glu Glu Gly Lys Glu Ile
 645 650 655
 Arg Lys Ala Ile Val Pro Gln Asp Pro Asp Trp Trp Ile Val Ser Ala
 660 665 670
 Asp Tyr Ser Gln Ile Glu Leu Arg Ile Leu Ala His Leu Ser Gly Asp
 675 680 685
 Glu Asn Leu Val Lys Ala Phe Glu Glu Gly Ile Asp Val His Thr Leu
 690 695 700
 Thr Ala Ser Arg Ile Tyr Asn Val Lys Pro Glu Glu Val Asn Glu Glu
 705 710 715 720
 Met Arg Arg Val Gly Lys Met Val Asn Phe Ser Ile Ile Tyr Gly Val
 725 730 735
 Thr Pro Tyr Gly Leu Ser Val Arg Leu Gly Ile Pro Val Lys Glu Ala
 740 745 750
 Glu Lys Met Ile Ile Ser Tyr Phe Thr Leu Tyr Pro Lys Val Arg Ser
 755 760 765
 Tyr Ile Gln Gln Val Val Ala Glu Ala Lys Glu Lys Gly Tyr Val Arg
 770 775 780
 Thr Leu Phe Gly Arg Lys Arg Asp Ile Pro Gln Leu Met Ala Arg Asp
 785 790 795 800
 Lys Asn Thr Gln Ser Glu Gly Glu Arg Ile Ala Ile Asn Thr Pro Ile
 805 810 815
 Gln Gly Thr Ala Ala Asp Ile Ile Lys Leu Ala Met Ile Asp Ile Asp
 820 825 830
 Glu Glu Leu Arg Lys Arg Asn Met Lys Ser Arg Met Ile Ile Gln Val
 835 840 845
 His Asp Glu Leu Val Phe Glu Val Pro Asp Glu Glu Lys Glu Glu Leu
 850 855 860
 Val Asp Leu Val Lys Asn Lys Met Thr Asn Val Val Lys Leu Ser Val
 865 870 875 880

-69-

Pro Leu Glu Val Asp Ile Ser Ile Gly Lys Ser Trp Ser
885 890

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Pro Ser Phe Ala Leu Asp Leu Glu Thr Ser Ser
1 5 10

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Pro Val Phe Ala Phe Asp Thr Glu Thr Asp Ser
1 5 10

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

-70-

Gly Pro Val Ala Phe Asp Ser Glu Thr Ser Ala
1 5 10

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Met Ile Val Ser Asp Ile Glu Ala Asn Ala
1 5 10

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GACGTTTCAA GCGCTAGGGC AAAAGA

26

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Lys Met Val Asn Phe Ser Ile Ile Tyr Gly

-71-

1 5 10

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Lys Ala Ile Asn Phe Gly Leu Ile Tyr Gly
1 5 10

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Lys Ala Ile Thr Phe Gly Ile Leu Tyr Gly
1 5 10

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Lys Thr Phe Ile Tyr Gly Phe Leu Tyr Gly

-72-

1 5 10

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Lys Thr Ile Asn Phe Gly Val Leu Tyr Gly
1 5 10

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GTATATTATA GAGTAGTTAA CCATCTTTCC A

31

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

GTAGGCCAGG GGCTGTGCCG GCAAAGAGAA ATAGTC

36

-73-

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 35 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GAAGGATATC CTTGGCGCCG GTTATTATGA AAATC

35

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1310 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: both
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

ATGGCGAGAC TATTCTCTT TGATGGCACA GCCCTGGCCT ACAGGGCATA TTACGCCCTC	60
GACAGATCCC TTTCCACATC CACAGGAATT CCAACGAACG CCGTCTATGG CGTTGCCAGG	120
ATGCTCGTTA AATTCATTAA GGAACACATT ATACCCGAAA AGGACTACGC GGCTGTGGCC	180
TTTGACAAGA AGGCAGCGAC GTTCAGACAC AAACCTGCTCG TAAGCGACAA GGCGCAAAGG	240
CCAAAGACGC CGGCTCTTCT AGTTCAGCAG CTACCTTACA TCAAGCGGCT GATAGAAGCT	300
CTTGTTTTCA AAGTGCTGGA GCTGGAAGGG TACGAAGCAG ACGATATCAT CGCCACGCTT	360
GCAGCAAAGG GCTGCACGTT TTTTGATGAG ATTTTCATAA TAACCGGTGA CAAGGATATG	420
CTTCAACTTG TAAACGAGAA GATAAAGGTC TGGAGAATCG TCAAGGGGAT ATCGGATCTT	480
GAGCTTTACG ATTCGAAAAA GGTGAAAGAA AGATACGGTG TGAACCACA TCAGATACCG	540
GATCTTCTAG CACTGACGGG AGACGACATA GACAACATTC CCGGTGTAAC GGAATAGGT	600
GAAAAGACCG CTGTACAGCT TCTCGGCAAG TATAGAAATC TTGAATACAT TCTGGAGCAT	660
CCCCGTGAAC TCCCCCAGAG AGTGAGAAAG GCTCTCTTGA GAGACAGGGA AGTTGCCATC	720

-74-

CTCAGTAAAA AACTTGCAAC TCTGGTGACG AACGCACCTG TTGAAGTGA CTGGGAAGAG	780
ATGAAATACA GAGGATACGA CAAGAGAAAA CTA CTCTCCGA TATTGAAAGA ACTGGAGTTT	840
GCTTCCATCA TGAAGGAACT TCAACTGTAC GAAGAAGCAG AACCCACCGG ATACGAAATC	900
GTGAAGGATC ATAAGACCTT CGAAGATCTC ATCGAAAAGC TGAAGGAGGT TCCATCTTTT	960
GCCCTGGACC TTGAAACGTC CTCCTTGGAC CCGTTCAACT GTGAGATAGT CGGCATCTCC	1020
GTGTCGTTCA AACCGAAAAC AGCTTATTAC ATTCCACTTC ATCACAGAAA CGCCCACAAT	1080
CTTGATGAAA CACTGGTGCT GTCGAAGTTG AAAGAGATCC TCGAAGACCC GTCTTCGAAG	1140
ATTGTGGGTC AGAACCTGAA GTACGACTAC AAGGTTCTTA TGGTAAAGGG TATATCGCCA	1200
GTTTATCCGC ATTTTGACAC GATGATAGCT GCATATTTGC TGGAGCCAAA CGAGAAAAAA	1260
TTCAATCTCG AAGATCTGTC TTTGAAATTT CTCGGATACA AAATGACGTC	1310

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 436 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Met	Ala	Arg	Leu	Phe	Leu	Phe	Asp	Gly	Thr	Ala	Leu	Ala	Tyr	Arg	Ala
1				5					10					15	
Tyr	Tyr	Ala	Leu	Asp	Arg	Ser	Leu	Ser	Thr	Ser	Thr	Gly	Ile	Pro	Thr
			20					25					30		
Asn	Ala	Val	Tyr	Gly	Val	Ala	Arg	Met	Leu	Val	Lys	Phe	Ile	Lys	Glu
		35					40					45			
His	Ile	Ile	Pro	Glu	Lys	Asp	Tyr	Ala	Ala	Val	Ala	Phe	Asp	Lys	Lys
	50					55						60			
Ala	Ala	Thr	Phe	Arg	His	Lys	Leu	Leu	Val	Ser	Asp	Lys	Ala	Gln	Arg
	65				70					75				80	
Pro	Lys	Thr	Pro	Ala	Leu	Leu	Val	Gln	Gln	Leu	Pro	Tyr	Ile	Lys	Arg
			85					90						95	
Leu	Ile	Glu	Ala	Leu	Gly	Phe	Lys	Val	Leu	Glu	Leu	Glu	Gly	Tyr	Glu
		100						105						110	

-75-

Ala Asp Asp Ile Ile Ala Thr Leu Ala Ala Lys Gly Cys Thr Phe Phe
 115 120 125
 Asp Glu Ile Phe Ile Ile Thr Gly Asp Lys Asp Met Leu Gln Leu Val
 130 135 140
 Asn Glu Lys Ile Lys Val Trp Arg Ile Val Lys Gly Ile Ser Asp Leu
 145 150 155 160
 Glu Leu Tyr Asp Ser Lys Lys Val Lys Glu Arg Tyr Gly Val Glu Pro
 165 170 175
 His Gln Ile Pro Asp Leu Leu Ala Leu Thr Gly Asp Asp Ile Asp Asn
 180 185 190
 Ile Pro Gly Val Thr Gly Ile Gly Glu Lys Thr Ala Val Gln Leu Leu
 195 200 205
 Gly Lys Tyr Arg Asn Leu Glu Tyr Ile Leu Glu His Ala Arg Glu Leu
 210 215 220
 Pro Gln Arg Val Arg Lys Ala Leu Leu Arg Asp Arg Glu Val Ala Ile
 225 230 235 240
 Leu Ser Lys Lys Leu Ala Thr Leu Val Thr Asn Ala Pro Val Glu Val
 245 250 255
 Asp Trp Glu Glu Met Lys Tyr Arg Gly Tyr Asp Lys Arg Lys Leu Leu
 260 265 270
 Pro Ile Leu Lys Glu Leu Glu Phe Ala Ser Ile Met Lys Glu Leu Gln
 275 280 285
 Leu Tyr Glu Glu Ala Glu Pro Thr Gly Tyr Glu Ile Val Lys Asp His
 290 295 300
 Lys Thr Phe Glu Asp Leu Ile Glu Lys Leu Lys Glu Val Pro Ser Phe
 305 310 315 320
 Ala Leu Asp Leu Glu Thr Ser Ser Leu Asp Pro Phe Asn Cys Glu Ile
 325 330 335
 Val Gly Ile Ser Val Ser Phe Lys Pro Lys Thr Ala Tyr Tyr Ile Pro
 340 345 350
 Leu His His Arg Asn Ala His Asn Leu Asp Glu Thr Leu Val Leu Ser
 355 360 365
 Lys Leu Lys Glu Ile Leu Glu Asp Pro Ser Ser Lys Ile Val Gly Gln
 370 375 380
 Asn Leu Lys Tyr Asp Tyr Lys Val Leu Met Val Lys Gly Ile Ser Pro
 385 390 395 400

-76-

Val Tyr Pro His Phe Asp Thr Met Ile Ala Ala Tyr Leu Leu Glu Pro
405 410 415

Asn Glu Lys Lys Phe Asn Leu Glu Asp Leu Ser Leu Lys Phe Leu Gly
420 425 430

Tyr Lys Met Thr
435

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 687 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: both
(D) TOPOLOGY: both

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

TCGTACCNGG	GNTCNCNANA	TCGACTGCAG	CATGCAAGCT	GGCTAATCAT	GGTCATAGCT	60
GTTTCCTGTG	TGAAATTGTT	ATCCGCTCAC	AATTCCACAC	AACATACGAG	CCGGAAGCAT	120
AAAGTGTAAG	GCCTGGGGTG	CCTAATGAGT	GAGCTAACTC	ACATTAAATTG	CGTTGCGCTC	180
ACTGCCCGCT	TTCCAGTCGG	GAAACCTGTC	GTGCCAGCTG	CATTAATGAA	TCGGCCAACG	240
CGCGGGGAGA	GGCGGTTTGC	GTATTGGGCG	CTCTTCCGCT	TCCTCGCTCA	CTGACTCGCT	300
GCGCTCGGTC	GTTTCGGCTGC	GGCGAGCGGT	ATCAGCTCAC	TCAAAGGCGG	TAATACGGTT	360
ATCCACAGAA	TCAGGGGATA	ACGCAGGAAA	GAACATGTGA	GCAAAGGCC	AGCAAAGGC	420
CAGGAACCGT	TAAAAAGGCC	GCGTTGCTGG	GCGTTTTTCC	ATAGGCTCCG	CCCCCCTTGA	480
CGAGCATCAC	AAAAATTCTGA	CGCTTCAAGT	TCAGAGGTGG	GCGAAACCCG	ACAGGGACTA	540
TAAAGATTAC	CAGGGCGTTT	TCCCCCTGGG	AAGCTNCCTT	CGTGCGCTCT	CCTGTTCCCCG	600
AACCTGGCCG	GTTTAACCGG	GATACCNGNT	CGGCCTTTTN	TCCCCCTTNGG	GGGAANCCTT	660
GGGGNTTTTN	GNAAAANGCT	AAGGGTT				687

(2) INFORMATION FOR SEQ ID NO:20:

-77-

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 701 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: both

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

GCTCGTACCG GGGATCTNNN ANATCGACTG CAGCATGCAA GCTTGGCGTA ATCATGGTCA	60
TAGCTGTTTC CTGTGTGAAA TTGTTATCCG CTCACAATTC CACACAACAT ACGAGCCGGA	120
AGCATAAAGT GTAAAGCCTG GGGTGCCTAA TGAGTGAGCT AACTCACATT AATTGCGTTG	180
CGCTCACTGC CCGCTTTCCA GTCGGGAAAC CTGTCGTGCC AGCTGCATTA ATGAATCGGC	240
CAACGCGCGG GGAGAGGCGG TTTGCGTATT GGGCGCTCTT CCGCTTCCTC GCTCACTGAC	300
TCGCTGCGCT CGGTCGTTTC GCTGCGGCGA GCGGTATCAG CTCACTCAAA GGCGGTAATA	360
CGGTTATCCA CAGAATCAGG GGATAACGCA GGAAAGAACA TGTGAGCAA AGGCCAGCAA	420
AAGGCCAGGA ACCGTAAAAA GGCCGCGTTG CTGGGCGTTT TTTCCATAGG CTCCGCCCCC	480
CTGANGAGCA TCANAAAAAT CGANGCTCAN GTCANAGGTG GCGAAACCCG ACAGGNCTAT	540
TAAAGATNC CCAGGCGTTT TCCCCCTGG GAAGCTCCCT CGTGGGGCTC TCCTGGTTNC	600
GGNNCCCTGN CCGGNTTACC GGGGATAANC TTGTTCCGGN CTTTNTCCCC TTCNGGGAAA	660
ANGGTGGGGG GTTTNTNNA AAAGGCTCAA AGGCTGGTAN G	701

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 717 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: both

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

GNTNTAGNNN GGNCTAANNG GCGGGGAAAT CGAGCTCGGT ACCCGGGGAT CCTCTAGAGT	60
---	----

-78-

CGACCTGCAG GCATGCAAGC TTGGCGTAAT CATGGTCATA GCTGTTTCCT GTGTGAAATT	120
GTTATCCGCT CACAATTCCA CACAACATAC GAGCCGGAAG CATAAAGTGT AAAGCCTGGG	180
GTGCCTAATG AGTGAGCTAA CTCACATTAA TTGCGTTGCG CTCACTGCCC GCTTTCCAGT	240
CGGGAAACCT GTCGTGCCAG CTGCATTAAAT GAATCGGCCA ACGCGCGGGG AGAGGCGGTT	300
TGCGTATTGG GCGCTCTTCC GCTTCCTCGC TCACTGACTC GCTGCGCTCG GTCGTTCCGC	360
TGCGGCGAGC GGTATCAGCT CACTCAAAGG CGGTAATACG GTTATCCACA GAAATCAGGG	420
GATAACGCAG GGAAAGAACA TGTGAGCAAA AGGCCAGCA AAAGGCCAGG AACCCGTAAA	480
AAGGCCGCGT TGCCTGGCGT TTTTCCATAG GCTCCGCCCC CCTTGACGAG CAATCACAAA	540
AATCGACGCT CAAAGTCAAG AGGTGGCGAA ACCCCGACAG GGACTTATAA AGATACCCAG	600
GCCGTTTCCC CCTGGAAGCT CCCCTCCGTG CGCTTCTCCT TGGTTCCCGA CCCTGCCGCT	660
TTACCNNGGAT NCCTGTCCGC CTTTTNTTCC CTTTCNGGNA ACCGGGCGCT TTTTTTT	717

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 713 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: both

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

NNNNC>NNNNG GCTGANAGCG ATAAATCGAG CTCGGTACCC GGGGATCCTC TAGAGTCGAC	60
CTGCAGGCAT GCAAGCTTGG CGTAATCATG GTCATAGCTG TTTCTGTGT GAAATTGTTA	120
TCCGCTCACA ATTCCACACA ACATACGAGC CGGAAGCATA AAGTGTAAG CCTGGGGTGC	180
CTAATGAGTG AGCTAACTCA CATTAATTGC GTTGCGCTCA CTGCCCCTT TCCAGTCGGG	240
AAACCTGTCTG TGCCAGCTGC ATTAATGAAT CGGCCAACGC GCGGGGAGAG GCGGTTTGCG	300
TATTGGGCGC TCTTCCGCTT CCTCGCTCAC TGA CTGCTG CGCTCGGTCG TTCGGCTGCG	360
GCGAGCGGTA TCAGCTCACT CAAAGGCGGT AATACGGTTA TCCACAGAAT CAGGGGATAA	420
CGCAGGAAAG AACATGTTGA GCAAAAGGCC AGCAAAAGGC CAGGAACCGT AAAAAGGCCG	480

-79-

CGTTTGCTGG CGTTTTTCCC ATAGGCTCCG CCCCCCTTGA CGAACCATCA CAAAAATCGA	540
CGCTCAATTC AGAAGTTGGC GAAAACCCGA CAGGACTAAT AAAGATACCC AGCGTTTCCC	600
CCCCTGGAAA CTCCCCTCCG TTGCGCCTCT CCCTGTTCCC GAACCTTGCC CGCTTACCGG	660
GAATACCTTG TCCNCCTTTT CTCCCCTTCC GGGAANC GTT NGCGCCTTTC CCC	713

What Is Claimed Is:

1. A *Thermotoga* DNA polymerase mutant which is modified at least one way selected from the group consisting of

5 (a) to reduce or eliminate the 3'-5' exonuclease activity of the polymerase;

(b) to reduce or eliminate the 5'-3' exonuclease activity of the polymerase; and

(c) to reduce or eliminate discriminatory behavior against a dideoxynucleotide.

10 2. The DNA polymerase mutant of claim 1, which is modified at least two ways.

3. The DNA polymerase mutant of claim 1, which is modified three ways.

15 4. The DNA polymerase mutant of claim 1, which comprises a mutation in the O-helix of said DNA polymerase resulting in said DNA polymerase becoming non-discriminating against dideoxynucleotides.

5. The DNA polymerase of claim 4, wherein said O-helix is defined as RXXXXXXXFXXX⁷³⁰YX, wherein X is any amino acid.

20 6. The DNA polymerase of claim 5, wherein said mutant DNA polymerase is a *Tne* DNA polymerase.

7. The *Tne* DNA polymerase as claimed in claim 6, wherein said mutation is a Phe⁷³⁰→Tyr⁷³⁰ substitution.

-81-

8. The DNA polymerase mutant of claim 1, wherein said DNA polymerase is a *Tne* DNA polymerase having substantially reduced 3'-5' exonuclease activity.

5 9. The mutant *Tne* DNA polymerase as claimed in claim 8, wherein said mutant is a Asp³²³→Ala³²³ substitution.

10. The mutant *Tne* DNA polymerase as claimed in claim 6, wherein said mutant polymerase comprises both a Phe⁷³⁰→Tyr⁷³⁰ substitution and a Asp³²³→Ala³²³ substitution.

10 11. The mutant DNA polymerase mutant of claim 1, wherein said DNA polymerase is a *Tne* DNA polymerase having substantially reduced 5'-3' exonuclease activity.

12. The mutant *Tne* DNA polymerase as claimed in claim 11, wherein said mutant polymerase has a deletion mutation in the N-terminal 5'-3' exonuclease domain.

15 13. The mutant *Tne* DNA polymerase as claimed in claim 12, wherein said mutant polymerase is devoid of the 219 N-terminal amino acids.

14. The DNA polymerase as claimed in claim 1, which is a mutant *Tma* polymerase.

20 15. The DNA polymerase as claimed in claim 14, wherein said polymerase has a Phe⁷³⁰→Tyr⁷³⁰ substitution.

16. The DNA polymerase of claim 14, wherein said DNA polymerase has substantially reduced 3'-5' exonuclease activity.

-82-

17. The mutant *Tma* DNA polymerase as claimed in claim 16, wherein said mutant is a Asp³²³→Ala³²³ substitution.

18. The mutant *Tma* DNA polymerase as claimed in claim 14, wherein said mutant polymerase comprises both a Phe⁷³⁰→Tyr⁷³⁰ substitution and a Asp³²³→Ala³²³ substitution.

19. The mutant DNA polymerase mutant of claim 14, wherein said DNA polymerase is a *Tma* DNA polymerase having substantially reduced 5'→3' exonuclease activity.

20. The mutant *Tma* DNA polymerase as claimed in claim 19, wherein said mutant polymerase has a deletion mutation in the N-terminal 5'→3' exonuclease domain.

21. The mutant *Tma* DNA polymerase as claimed in claim 20, wherein said mutant polymerase is devoid of the 219 or less N-terminal amino acids.

22. A vector comprising a gene encoding the DNA polymerase of claim 1.

23. The vector of claim 22, wherein said gene is operably linked to a promoter.

24. The vector of claim 23, wherein said promoter is selected from the group consisting of a λ -P_L promoter, a *tac* promoter, a *trp* promoter, and a *trc* promoter.

25. A host cell comprising the vector of claim 22.

-83-

26. A method of producing a DNA polymerase, said method comprising:

- (a) culturing the host cell of claim 25;
- (b) expressing said gene; and
- (c) isolating said DNA polymerase from said host cell.

27. The method of claim 26, wherein said host cell is *E. coli*.

28. A method of synthesizing a double-stranded DNA molecule comprising:

- (a) hybridizing a primer to a first DNA molecule; and
- (b) incubating said DNA molecule of step (a) in the presence

of one or more deoxy- or dideoxyribonucleoside triphosphates and the DNA polymerase of claim 1, under conditions sufficient to synthesize a second DNA molecule complementary to all or a portion of said first DNA molecule.

29. The method of claim 28, wherein said deoxy- or dideoxyribonucleoside triphosphates are selected from the group consisting of dATP, dCTP, dGTP, dTTP, dITP, 7-deaza-dGTP, 7-deaza-dATP, dUTP, ddATP, ddCTP, ddGTP, ddITP, ddTTP, [α -S]dATP, [α -S]dTTP, [α -S]dGTP, and [α -S]dCTP.

30. The method of claim 28, wherein one or more of said deoxyribonucleoside triphosphates are detectably labeled.

31. A method of sequencing a DNA molecule, comprising:

- (a) hybridizing a primer to a first DNA molecule;
- (b) contacting said DNA molecule of step (a) with

deoxyribonucleoside triphosphates, the DNA polymerase of claim 1, and a terminator nucleotide;

-84-

(c) incubating the mixture of step (b) under conditions sufficient to synthesize a random population of DNA molecules complementary to said first DNA molecule, wherein said synthesized DNA molecules are shorter in length than said first DNA molecule and wherein said synthesized DNA molecules comprise a terminator nucleotide at their 3' termini; and

(d) separating said synthesized DNA molecules by size so that at least a part of the nucleotide sequence of said first DNA molecule can be determined.

32. The method of claim 31, wherein said deoxyribonucleoside triphosphates are selected from the group consisting of dATP, dCTP, dGTP, dTTP, dITP, 7-deaza-dGTP, 7-deaza-dATP, dUTP, [α -S]dATP, [α -S]dTTP, [α -S]dGTP, and [α -S]dCTP.

33. The method of claim 31, wherein said terminator nucleotide is ddTTP, ddATP, ddGTP or ddCTP.

34. The method of claim 31, wherein one or more of said deoxyribonucleoside triphosphates is detectably labeled.

35. The method of claim 31, wherein one or more of said terminator nucleotides is detectably labeled.

36. The method of claim 31, wherein said primer is detectably labeled.

37. A method for amplifying a double stranded DNA molecule, comprising:

(a) providing a first and second primer, wherein said first primer is complementary to a sequence at or near the 3'-termini of the first strand

-85-

of said DNA molecule and said second primer is complementary to a sequence at or near the 3'-termini of the second strand of said DNA molecule;

5 (b) hybridizing said first primer to said first strand and said second primer to said second strand in the presence of the DNA polymerase of claim 1, under conditions such that a third DNA molecule complementary to said first strand and a fourth DNA molecule complementary to said second strand are synthesized;

(c) denaturing said first and third strand, and said second and fourth strands; and

10 (d) repeating steps (a) to (c) one or more times.

38. The method of claim 37, wherein said deoxyribonucleoside triphosphates are selected from the group consisting of dATP, dCTP, dGTP, dTTP, dITP, 7-deaza-dGTP, 7-deaza-dATP, dUTP, [α -S]dATP, [α -S]dTTP, [α -S]dGTP, and [α -S]dCTP.

15 39. A kit for sequencing a DNA molecule, comprising:

(a) a first container means comprising the DNA polymerase of claim 1;

(b) a second container means comprising one or more dideoxyribonucleoside triphosphates; and

20 (c) a third container means comprising one or more deoxyribonucleoside triphosphates.

40. A kit for amplifying a DNA molecule, comprising:

(a) a first container means comprising the DNA polymerase of claim 1; and

25 (b) a second container means comprising one or more deoxyribonucleoside triphosphates.

-86-

41. A mutant DNA polymerase having substantially reduced or eliminated 5'-3' exonuclease activity, wherein at least one of the amino acids corresponding to Asp⁸, Glu¹¹², Asp¹¹⁴, Asp¹¹⁵, Asp¹³⁷, Asp¹³⁹, Gly¹⁰², Gly¹⁸⁷, or Gly¹⁹⁵ of *Tne* DNA polymerase has been mutated.

5 42. The mutant DNA polymerase of claim 41, which is a mutant *E. coli* poll, *Taq*, *Tne* or *Tma* DNA polymerase.

43. The mutant DNA polymerase of claim 42, which is a *Tne* DNA polymerase.

10 44. The mutant DNA polymerase of claim 43, which is a *Tma* DNA polymerase.

45. A vector coding for the mutant DNA polymerase of claim 41.

46. A host cell comprising the vector of claim 45.

15 47. A method of producing a mutant DNA polymerase having substantially reduced or eliminated 5'-3' exonuclease activity, wherein at least one of the amino acids corresponding to Asp⁸, Glu¹¹², Asp¹¹⁴, Asp¹¹⁵, Asp¹³⁷, Asp¹³⁹, Gly¹⁰², Gly¹⁸⁷, or Gly¹⁹⁵ of *Tne* DNA polymerase has been mutated, comprising

- 20 (a) culturing the host cell of claim 46;
(b) expressing the mutant DNA polymerase; and
(c) isolating said mutant DNA polymerase.

48. A method of preparing cDNA from mRNA, comprising

- (a) contacting mRNA with an oligo(dT) primer or other complementary primer to form a hybrid, and

-87-

(b) contacting said hybrid formed in step (a) with the *Tne* DNA polymerase of claim 1 and dATP, dCTP, dGTP and dTTP, whereby a cDNA-RNA hybrid is obtained.

49. A method of preparing dsDNA from mRNA, comprising

5 (a) contacting mRNA with an oligo(dT) primer or other complementary primer to form a hybrid, and

(b) contacting said hybrid formed in step (a) with the *Tne* DNA polymerase claim 1, dATP, dCTP, dGTP and dTTP, and an oligonucleotide which is complementary to the first strand cDNA;

10 whereby dsDNA is obtained.

1/30




FIG.1

2/30




FIG.2

3/30




FIG.3

4/30




FIG.4

5/30

BamHI

1 GGATCCAGAC TGGTGGATCG TCACTGCGGA TTATTCCCAA ATAGAACTCA GAATCCTCGC
G S R L V D R Q C G L F P N R T Q N P R
→ D P D W W I V S A D Y S Q I E L R I L
I Q T G G S S V R I I P K - N S E S S

61 TCATCTCAGT GGTGATGAGA ACCTTGTA GGCCTTCGAG GAGGGCATCG ATGTGCACAC
S S Q W - - E P C E G L R G G H R C A H
→ A H L S G D E N L V K A F E E G I D V H
L I S V V M R T L - R P S R R A S M C T

121 CTTGACTGCC TCCAGCATCT ACAACGTAA GCCAGAAGAA GTGAACGAAG AAATGCGACG
L D C L Q D L Q R K A R R S E R R N A T
→ T L T A S R I Y N V K P E E V N E E M R
P - L P P G S T T - S Q K K - T K K C D

181 GGTGGAAG ATGGTGAAC TCTCTATAAT ATACGGTGTG ACACCGTACG GTCTTTCTGT
G W K D G E L L Y N I R C H T V R S F C
→ R V G K M V N (F) S I I Y G V T P Y G L S
G L E R W - T S L - Y T V S H R T V F L

241 GAGACTTGA ATACCGGTA AAGAAGCAGA AAAGATGATT ATCAGCTATT TCACACTGTA
E T W N T G - R S R K D D Y Q L F H T V
→ V R L G I P V K E A E K M I I S Y F T L
- D L E Y R L K K Q K R - L S A I S H C

301 TCCAAAGGTG CGAAGCTACA TCCAGCAGGT TGTTCAGAG GCAAAAGAGA AGGCTACGT
S K G A K L H P A G C C R G K R E G L R
→ Y P K V R S Y I Q Q V V A - E A K E K G Y
I Q R C E A T S S R L L Q R Q K R R A T

361 CAGGACTCTC TTTGGAAGAA AAAGAGATAT TCCCCAGCTC ATGGCAAGGG ACAAGAACAC
Q D S L W K K K R Y S P A H G K G Q E H
→ V R T L F G R K R D I P Q L M A R D K N
S G L S L E E K E I F P S S W Q G T R T

421 CCACTCCGAA GCGGAAAGAA TCGCAATAAA CACCCCCATT CAGGGAAGTG CGGCAGATAT
P V R R R K N R N K H P H S G N C G R Y
→ T Q S E G E R I A I N T P I Q G T A A D
P S P K A K E S Q - T P P F R E L R Q I

FIG.5A

6/30

481 AATAAAATTG GCTATGATAG ATATAGACGA GGAGCTGAGA AAAAGAAACA TGAATCCAG
N K I G Y D R Y R R G A E K K K H E I Q
→ I I K L A M I D I D E E L R K R N M K S
- - N W L - - I - T R S - E K E T - N P

541 AATGATCATT CAGGTTGATG ACGAACTGGT CTTGAGGTT CCCGATGAGG AAAAAGAAGA
N D H S G S - R T G L R G S R - G K R R
→ R M I I Q V H D E L V F E V P D E E K E
E - S F R F M T N W S S R F P M R K K K

601 ACTAGTTGAT CTGGTGAAGA ACAAATGAC AAATGTGGTG AAATCTCTG TGCCTCTTGA
T S - S G E E Q N D K C G E T L C A S -
→ E L V D L V K N K M T N V V K L S V P L
N - L I W - R T K - Q M W - N S L C L L

661 GGTGACATA AGCATCGGAA AAAGCTGGTC TTGA
G - H K H R K K L V L
→ E V D I S I G K S W S -
R L T - A S E K A G L

FIG.5B

7/30




FIG.6A

8/30




FIG.6B




FIG.7

10/30





FIG.8



11/30

A B
A C G T G A T C




FIG.9

12/30



FIG.10




FIG.11





FIG.12






FIG.14A



FIG.14B





FIG.15



20/30




FIG.16B






FIG.16C

22/30





24/30

ATCANA A AATCG ANGCTC ANGTC ANAGG TGGCGA AACCC GACA GG NCT ATTAAAAG ATNCCCAGG CGTTTT
490 500 510 520 530 540 550 560



CCCCC TGG AAGCTCCC TCG TCGGGCTC TCC TGG TTNCGGNCCCIGNCCGNTTIA CCG GGGAT AACTTGTCCGGNCTT TTT
570 580 590 600 610 620 630 640



CCC T T CNGGG AAAANGGTGGGGGTTTNTNNAA AAGCCTCAA GGCTGGTANG
650 660 670 680 690 700



FIG.16F






FIG.17A

26/30

CGGCGGGGAGAGCGGTTTGGCTATTGGGCGCTCTTCCGCTTCCTCGCTCAGTACTCGCTGCGCTCGGTCGTTCCGGC
290 300 310 320 330 340 350 360



TGCGGCGAGCGGTATCAGCTCACCTCAAGCGCGGTAATACGGTTATCCACAGAAATCAGGGGATAACGCCAGG
370 380 390 400 410 420 430 440




GAAAGACATGTGAGCAAAAGGCCCAGCAAGGCCAGGAACCCGTAAAAAGGCCCGCGTTGCCCGCGGTTTT
440 450 460 470 480 490 500



FIG.17B

27/30







FIG.17D



T T T C C C A T A G G C T C C G C C C C C C T T G A C G A A C C A T C G A C G C T C A A T T C A G A A G T T G C G A A A A C C C G
500 510 520 530 540 550 560





FIG.17F

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/14189

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) : C12Q 1/68; C12P 19/34; C12N 15/64, 9/00, 1/20, 15/00; C07H 21/02 US CL : 435/91.2, 91.1, 91.4, 183, 252.33, 172.3, 69.1; 536/ 23.1 According to International Patent Classification (IPC) or to both national classification and IPC																				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/91.2, 91.1, 91.4, 183, 252.33, 172.3, 69.1; 536/ 23.1 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet.																				
C. DOCUMENTS CONSIDERED TO BE RELEVANT																				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
Y	EP 0 655 506 A1 (THE PRESIDENT & FELLOWS OF HARVARD COLLEGE) 31 May 1995, see entire document.	1-49																		
Y, P	US H1531 A (BLUMENTHALS et al.) 07 May 1996, see entire document.	1-49																		
Y, P	Slater, et al. DNA Polymerase I of Thermatoga Neopolitane (Tne) and Mutant Derivatives, Seventh International Genome Sequencing and Analysis Conference, 16-20 September, 1995, Abstract. See entire document.	1-3, 8, 22-40, 48, 49																		
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																				
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>*T</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A* document defining the general state of the art which is not considered to be of particular relevance</td> <td>*X*</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*E* earlier document published on or after the international filing date</td> <td>*Y*</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>*G*</td> <td>document member of the same patent family</td> </tr> <tr> <td>*O* document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td>*P* document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G*	document member of the same patent family	*O* document referring to an oral disclosure, use, exhibition or other means			*P* document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																		
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																		
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																		
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G*	document member of the same patent family																		
O document referring to an oral disclosure, use, exhibition or other means																				
P document published prior to the international filing date but later than the priority date claimed																				
Date of the actual completion of the international search 07 NOVEMBER 1996		Date of mailing of the international search report 26 NOV 1996																		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer, DW AR DIANNE REES Telephone No. (703) 308-0196																		

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/14189

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, AIDSLINE, BIOSIS, BIOTECHABS, BIOBUSINESS, CABA, CAPLUS, CANCERLIT, DRUGU, EMBASE, IFIPAT, JAPIO, LIFESCI, MEDLINE, USPATFUL, WPIDS

search terms: DNA polymerase, Theratoga, modified, mutant, discriminating, nondiscriminating, incorporation, dideoxynucleotides, O-helix, exonuclease, Phe, Tyr, Asp, Ala, deletions, truncations.